

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

CONSOLIDATED FINANCIAL STATEMENTS AND FOOTNOTES FOR  
THE PERIOD JANUARY 1–DECEMBER 31, 2022

## INDEPENDENT AUDITOR'S REPORT

To Board of Directors of Ulusoy Un Sanayi ve Ticaret A.Ş.

### A. Audit of Consolidated Financial Statements

#### 1. Opinion

We have audited the consolidated financial statements consisting of the consolidated financial statement footnotes, including the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in shareholders' equity and the consolidated statement of cash flows and a summary of significant accounting policies for the accounting period ending on the same date as the consolidated statement of financial position dated 31 December 2022 of Ulusoy Un Sanayi ve Ticaret A.Ş. ("Company") and its subsidiaries (collectively referred to as the "Group");

In our opinion, the accompany in consolidated financial statements accurately present the Group's consolidated financial position as of 31 December, 2022, as well as its consolidated financial performances and consolidated cash flows in the accounting period ending on the same date, with all important aspects in accordance with the Türkiye Financial Reporting Standards (TFRS).

#### 2. Basis of Opinion

We conducted our audit in accordance with the Independent Audit Standards ("IAS"), a part of Turkish Audit Standards as published by Public Oversight Accounting and Auditing Standards Authority ("POAS"). Our responsibility under these standards are disclosed in detail in the section entitled "Independent Auditor's Responsibilities concerning Consolidated Financial Statements". We declare that we are independent of the Group in accordance with the Code of Conduct for Independent Auditors ("Code of Conduct") as published by POAS and ethic provisions contained in the related legislation regarding the auditing of financial statements. We have also fulfilled other responsibilities relating to the ethics under the Code of Conduct and legislation. We believe that the audit evidence we have obtained during the independent audit is sufficient and appropriate to provide a basis for our audit opinion.

### 3. Key Audit Issues

Key audit matters are those that, in our professional judgment, are of the most importance in our independent audit of the current period's consolidated financial statements. Key audit matters have been addressed in the context of our audit of the consolidated financial statements as a whole and in forming our opinion on the consolidated financial statements, on which we do not express a separate opinion.

Key Auditing Subjects	How the key auditing subject was handled in the audit
<b>Record of Revenue</b>	
<p>Revenue is the most important measurement criterion in terms of evaluating the results of the targeted target during the year and monitoring the performance.</p> <p>Group's revenue; It is a key expense for our audit as the transaction volume is high and it is significant in terms of the consolidated profit or loss statement for the accounting period 1 January - 31 December 2022. Explanations on the Group's policies and revenues Footnote 2.6. and Footnote 23.</p>	<p>The audit procedures we apply consist of understanding the internal controls related to the revenue recognition process, including the controls performed by the senior management, identifying and evaluating the controls in the processes, detailed analytical examinations and detailed tests.</p> <p>The risk of 'material misstatement' in the recognition of revenue in the consolidated financial statements is considered a significant risk, and our audit procedures in addressing this risk include the following:</p> <ul style="list-style-type: none"> <li>- Information technology processes were understood with the help of our information technology experts, and the controls identified in the relevant processes were tested within the scope of studies on the evaluation of the information technology general control environment.</li> <li>- Goods sales processes were understood and the automatic and manual controls included in the processes were determined and evaluated.</li> <li>- Evidence that revenue is recorded in the correct period in accordance with the periodicity principle has been tested for sample selected transactions.</li> <li>- The processes applied by the Group during the verification of trade receivables were understood and the balances of trade receivables selected through sampling were confirmed with the relevant companies.</li> </ul> <p>As a result of the audit procedures we have applied, no material difference that may cause errors in the consolidated financial statements has been found.</p> <p>In addition, it has been observed that the footnotes on revenue transactions comply with TFRS.</p>

### 3. Key Auditing Matters (Continued)

Key Auditing Subjects	How the key auditing subject was handled in the audit
<b>Tangible fixed assets accounted for at fair value</b>	
<p>As of 31 December 2022, tangible fixed assets, which have a significant share in the Group's total assets, are accounted for at their fair values.</p> <p>The accounting policies adopted by the Group management in the accounting of these assets are the fair value method, as detailed in Footnote 2.6 and Footnote 17, and the fair values of these assets are determined by an independent valuation firm authorized by the Capital Markets Board and after the evaluations of the Group management. are taken as the basis in the consolidated balance sheet as carried value.</p> <p>The fair value of these assets depends on the valuation method adopted and the inputs and assumptions in the valuation model.</p> <p>The study on the determination of the fair value of the said assets has been identified as a key audit matter due to the fact that the recorded values of the assets constitute a significant part of the total assets of the Group, and the subjective nature of the valuations includes important assumptions and judgments.</p>	<p>In our audit work, the following audit procedures have been applied regarding the subject:</p> <ul style="list-style-type: none"> <li>- The real estate valuation accreditation and license of the expert institution, which is appreciated by the Capital Markets Board, has been checked.</li> <li>- The competence, capability and impartiality of the expert body were evaluated.</li> <li>- The valuation reports prepared by the expert institution for each asset were read and the valuation studies were evaluated.</li> <li>- The compliance of the fair values in the valuation report with the footnotes has been checked, it has been evaluated whether the values in the footnotes are in agreement with the valuation reports and the footnote explanations are sufficient in terms of TFRS.</li> </ul>

### 3. Key Auditing Matters (Continued)

Key Auditing Subjects	How the key auditing subject was handled in the audit
<b>Recoverability of Trade Receivables</b>	
<p>As of 31 December 2022, trade receivables from unrelated parties amounting to 2.845.268.594 TL have a significant size in the consolidated financial statements.</p> <p>While evaluating the recoverability of the said trade receivables, the Group management; It takes into account past collection performances, maturity analysis, disputes or lawsuits related to receivables. As a result of all these evaluations, the determination of doubtful receivables and the determination of the provision amounts for these receivables also include the assumptions and estimates of the management.</p> <p>For these reasons, the recoverability of such receivables has been determined by us as a key audit matter.</p>	<p>During our audit, the following procedures were followed for the audit of the recoverability of trade receivables:</p> <ul style="list-style-type: none"> <li>- The Group's credit follow-up and credit risk management policy, including credit limit management, has been understood and evaluated.</li> <li>- Balances of trade receivables from unrelated parties were tested by sending confirmation letters by way of sampling.</li> <li>- Aging of trade receivable balances from unrelated parties has been analyzed.</li> <li>- Collections made in the following period were tested by sampling.</li> <li>- It was investigated whether there were any disputes or lawsuits regarding the collection of trade receivable balances from unrelated parties, and the evaluations of the ongoing lawsuits were received from the legal advisors.</li> <li>- Within the framework of the discussions with the Group management, it has been evaluated whether the basic assumptions and other judgments that form the basis of the impairment calculations are reasonable.</li> <li>- The appropriateness and adequacy of the disclosures in the footnotes of the consolidated financial statements regarding the recoverability of trade receivables from non-related parties in accordance with the relevant accounting standards have been evaluated.</li> </ul>

### 4. Emphasis of Matter

We draw attention to Footnote 8 of the consolidated financial statements, which explains the accounting policy and accounting procedures implemented by the Group within the scope of the contract signed with the Turkish Grain Board. This does not affect the opinion given by us.

## 5. Management and Senior Management's Responsibility for Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the TFRS, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material statement, whether due to fraud or error.

In preparing the consolidated financial statements, the management is also responsible for evaluating the capability of the Group to remain as a going concern and make disclosures as to going concern status as necessary and relies on the going concern status of the business insofar as there exists no intention or obligation to dissolve the business or end the commercial activity.

Senior management is responsible for the supervision of the financial reporting process of the Group.

## 6. Independent Auditor's Responsibilities for Independent Audit of the Financial Statements

The following are the responsibilities of the independent auditor in any independent audit:

We aim to obtain a reasonable assurance as to whether or not the financial statements as a whole do not involve any error or material misstatement, whether due to fraud, and prepare an independent audit report including our opinion. The reasonable assurance given upon any independent audit conducted in accordance with the IAS is a high level of assurance; however, does not guarantee the detection of any significant misstatement at all times. Errors and misstatements may arise from error or fraud. In case misstatements are solely or collectively expected to reasonably affect the economic decisions to be taken based on such financial statements, such misstatements are considered significant.

As a requirement of an independent audit conducted in accordance with IASs, we use our professional judgment and maintain our professional skepticism throughout the independent audit. Also by us:

- Determine and evaluate "material misstatements", whether due to error and/or fraud in the financial statements, design and implement audit procedures that address such risks and obtain sufficient and proper evidence which form basis for our opinion. A risk to not detect a significant misstatement due to fraud is higher than the risk to not detect any misstatement due to error based on the fact that fraud may include acts of collusion, fraud, willful negligence, misstatement or internal control violation.
- Evaluate the internal controls for the purpose of designing audit procedures in compliance with status, but not of providing opinion for the effectiveness of the internal control of the Group.

## 6. Independent Auditor's Responsibilities for Independent Audit of the Financial Statements (Continued)

- Evaluate the appropriateness of the accounting policies employed by the management and rationality of the disclosures regarding accounting predictions.
- Based on the audit evidence obtained, make a deduction as to existence of any significant uncertainty concerning any event or condition which may raise doubt in respect of the capability of the Group to remain as a going concern and as to the appropriateness of management's use of going concern principle. In case we deduct on the existence of a significant uncertainty, we are required to draw attention to the relevant disclosures in the financial statements in our report or provide any opinion other than unqualified opinion. The results we deduct are based on the audit evidence obtained until the date of the independent audit report. Moreover, any future event or condition may cease the going concern status of the Group.
- Evaluate whether or not consolidated financial statements reflect the transactions and events which comprise the basis of such financial statements so as to provide fair presentation with general presentation, structure and contents, including the notes to such financial statements.
- In order to express an opinion on the consolidated financial statements, sufficient and appropriate audit evidence is obtained about the financial information regarding the businesses or operating segments within the Group. We are responsible for the direction, supervision and conduct of the Group audit. We are also solely responsible for the audit opinion we give.

Alongside other matters, we inform the senior management as to the planned scope and timing of the independent audit including any significant internal control deficiencies detected during the audit, as well as significant audit results.

We have informed the senior management with which we establish compliance with the code of conduct as regards the independence. Furthermore, we have further informed the senior management about any and all relations and other matters which may impact the independence and any measures, if any.

## 6. Independent Auditor's Responsibilities for Independent Audit of the Financial Statements (Continued)

We select the key audit matters of great importance in the audit of the consolidated financial statements for the current annual reporting period among those already advised to the senior management. In cases where the legislation does not allow public disclosure or in exceptional cases where adverse results which may arise from public disclosure may be expected to exceed the public interest that public disclosure may bring about, we may decide upon the non-disclosure of such matter in the independent audit report.

### B. Other Obligations Arising from the Legislation

1. Pursuant to the fourth paragraph of Article 402 of the Turkish Commercial Code No. 6102 ("TCC"), the Company's bookkeeping system, financial statements, and the law and the Company's articles of association do not comply with the financial reporting provisions for the accounting period of January 1 – December 31, 2022. No significant issues were found.
2. Pursuant to the fourth paragraph of Article 402 of the TCC, the Board of Directors has given us the required explanations within the scope of the audit and the requested documents.
3. The Auditor's Report on the Early Detection of Risk System and Committee, prepared in accordance with the fourth paragraph of Article 398 of the TCC, was submitted to the Company's Board of Directors on March 10, 2023.

Finansal Eksen Bağımsız Denetim ve Danışmanlık A.Ş.

*Exclusive Member of GGI Global Alliance AG*

Ufuk Doğruer  
Principal Auditor in Charge

İstanbul, 10 March 2023



<b>CONTENTS</b>	<b>Page</b>
<b>CONSOLIDATED STATEMENT OF FINANCIAL POSITION (BALANCE SHEET)</b>	1 – 2
<b>CONSOLIDATED STATEMENT OF PROFIT OR LOSS</b>	3
<b>CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME</b>	4
<b>CONSOLIDATED STATEMENT OF CHANGES IN EQUITY</b>	5
<b>CONSOLIDATED STATEMENT OF CASH FLOW</b>	6
 <b>EXPLANATORY NOTES FOR THE CONSOLIDATED FINANCIAL STATEMENTS</b>	
FOOTNOTE 1    GROUP'S ORGANIZATION AND FIELD OF ACTIVITY	7-9
FOOTNOTE 2    GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS	10-24
FOOTNOTE 3    BUSINESS COMBINATIONS	25
FOOTNOTE 4    REPORTING BY SECTIONS	26-27
FOOTNOTE 5    CASH AND CASH EQUIVALENTS	28
FOOTNOTE 6    FINANCIAL INVESTMENTS	28-29
FOOTNOTE 7    FINANCIAL BORROWINGS	29-31
FOOTNOTE 8    TRADE RECEIVABLES AND PAYABLES	32-33
FOOTNOTE 9    OTHER RECEIVABLES AND PAYABLES	33
FOOTNOTE 10    DERIVATIVE INSTRUMENTS	34
FOOTNOTE 11    INVENTORIES	35
FOOTNOTE 12    PREPAID EXPENSES AND DEFERRED INCOME	35
FOOTNOTE 13    INVESTMENTS EVALUATED BY THE EQUITY METHOD	36
FOOTNOTE 14    INVESTMENT PROPERTIES	37
FOOTNOTE 15    ASSETS RELATED TO CURRENT PERIOD TAX	38
FOOTNOTE 16    RIGHT OF USE ASSETS	38
FOOTNOTE 17    TANGIBLE ASSETS	39-40
FOOTNOTE 18    INTANGIBLE ASSETS OTHER THAN GOODWILL	41
FOOTNOTE 19    PROVISIONS, CONTINGENT ASSETS AND LIABILITIES	42-43
FOOTNOTE 20    PROVISIONS WITHIN THE SCOPE OF EMPLOYEE BENEFITS	44-45
FOOTNOTE 21    OTHER ASSETS AND LIABILITIES	45
FOOTNOTE 22    EQUITY	46-48
FOOTNOTE 23    REVENUE AND COST OF SALES	49
FOOTNOTE 24    GENERAL ADMINISTRATIVE EXPENSES AND MARKETING EXPENSES	50-51
FOOTNOTE 25    OTHER INCOME AND EXPENSES FROM MAIN ACTIVITIES	52
FOOTNOTE 26    INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES	53
FOOTNOTE 27    FINANCIAL INCOME AND EXPENSES	54
FOOTNOTE 28    INCOME TAXES	55-59
FOOTNOTE 29    EARNINGS PER SHARE	59
FOOTNOTE 30    RELATED PARTY DISCLOSURES	60-62
FOOTNOTE 31    NATURE AND LEVEL OF RISKS ARISING FROM FINANCIAL INSTRUMENTS	63-68
FOOTNOTE 32    FINANCIAL INSTRUMENTS (FAIR VALUE DISCLOSURES AND DISCLOSURES WITHIN THE FRAMEWORK OF HEDGE ACCOUNTING)	69
FOOTNOTE 33    FEES FOR SERVICES RECEIVED FROM THE INDEPENDENT AUDITOR'S	69
FOOTNOTE 34    EVENTS AFTER THE REPORTING PERIOD	70

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE PERIOD AS OF DECEMBER 31, 2022**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION (BALANCE SHEET)**

*(All amounts are expressed in Turkish Lira (TRY) unless otherwise stated.)*

	Footnote No	Current Period	Previous Period
		<i>Audited</i>	<i>Audited</i>
Type of Financial Statement		Consolidated	Consolidated
Period		December 31, 2022	December 31, 2021
<b>ASSETS</b>			
<b>Current Assets</b>		<b>7.333.662.376</b>	<b>3.002.729.564</b>
Cash And Cash Equivalents	5	1.519.704.774	498.900.970
Financial Investment	6	1.047.908.349	36.038.234
Trade Receivables		2.946.838.510	1.153.061.819
- Trade Receivables from Related Parties	8,30	101.569.916	5.854.793
- Trade Receivables from Non-related Parties	8	2.845.268.594	1.147.207.026
Other Receivables		57.687.020	4.862.290
- Other Receivables from Related Parties	9,30	-	600
- Other Receivables from Non-related Parties	9	57.687.020	4.861.690
Derivative Instruments	10	144.075.641	225.374.770
Inventories	11	1.283.277.033	860.125.939
Prepaid Expenses	12	214.208.401	187.217.176
Assets Related to Current Period Tax	15	87.611.727	8.278.620
Other Current Assets	21	32.350.921	28.869.746
<b>Non-Current Assets</b>		<b>2.782.472.893</b>	<b>691.976.988</b>
Trade Receivables		10.197.097	10.197.097
- Trade Receivables from Non-related Parties	8	10.197.097	10.197.097
Other Receivables		832.953	543.541
- Other Receivables from Non-related Parties	9	832.953	543.541
Investments Valued by Equity Method	13	7.808.666	5.316.148
Investment Properties	14	968.000	16.292.000
Right-of-use Assets	16	5.985.770	3.657.701
Tangible Assets	17	2.420.638.382	592.884.673
Intangible Assets		65.074.527	3.587.810
- Goodwill	3	58.747.694	-
- Other Intangible Assets	18	6.326.833	3.587.810
Prepaid Expenses	12	23.502.406	8.027.627
Deferred Tax Assets	28	247.465.092	51.470.391
<b>TOTAL ASSETS</b>		<b>10.116.135.269</b>	<b>3.694.706.552</b>

*The attached footnotes constitute an integral part of these consolidated financial statements*

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE PERIOD AS OF DECEMBER 31, 2022**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION (BALANCE SHEET)**  
*(All amounts are expressed in Turkish Lira (TRY) unless otherwise stated.)*

		Current Period	Previous Period
		Audited	Audited
Type of Financial Statement	Footnote	Consolidated	Consolidated
Period	No	December 31, 2022	December 31, 2021
LIABILITIES			
Short-term Liabilities		5.972.906.227	2.565.639.858
Short-term Borrowings		1.620.635.261	1.051.300.420
- Bank Loans	7	1.620.635.261	1.051.300.420
Short-term Portions of Long-term Borrowings	7	772.569.856	266.558.959
Trade Payables		3.083.354.814	1.139.289.953
- Trade Payables to Related Parties	8,30	4.117.214	5.822.384
- Trade Payables to Unrelated Parties	8	3.079.237.600	1.133.467.569
Payables Related to Employee Benefits	20	11.158.749	2.701.254
Other Payables		205.591.252	8.835.403
- Other Payables to Related Parties	9,30	205.312.078	8.707.586
- Other Payables to Unrelated Parties	9	279.174	127.817
Derivative Instruments	10	65.554.675	55.543
Deferred Income	12	100.421.758	74.225.292
Short-term Provisions		17.333.752	582.474
- Short-term Provisions Related to Employee Benefits	20	3.032.935	157.474
- Other Short-term Provisions	19	14.300.817	425.000
Other Short-term Liabilities	21	96.286.110	22.090.560
Long-term Liabilities		1.328.167.344	400.871.188
Long-term Borrowings	7	839.994.216	282.251.126
Long-term Provisions		24.505.736	3.657.593
- Long-term Provisions Related to Employee Benefits	20	24.505.736	3.657.593
Deferred Tax Liability	28	463.667.392	114.962.469
Total Equity	22	2.815.061.698	728.195.506
Paid-in Capital		190.970.000	190.970.000
Repurchased Shares (-)		(64.567.763)	(26.765.386)
Premiums (Discounts) Related to Shares		15.269.029	15.269.029
Other Comprehensive Income (Expenses) not to be Reclassified to Profit or Loss		1.574.556.913	251.661.140
- Increases/Decreases in Tangible Assets Due to Revaluation		1.583.492.480	252.938.157
- Revaluation Gains (Losses) on Defined Benefit Plans		(8.791.736)	(1.238.083)
- Shares of Other Comprehensive Income from Investments Valued by the Equity Method Not to be Classified in Profit and Loss		(143.831)	(38.934)
Other Comprehensive Income (Expenses) to be Reclassified to Profit or Loss		144.881.024	55.993.439
- Foreign Currency Exchange Differences		144.881.024	55.993.439
Reserves on Retained Earnings		78.622.024	36.867.423
Retained Earnings or Losses		162.445.260	64.604.605
Net Profit or Loss for the Period		712.885.211	139.595.256
Parent Company Equity		2.815.061.698	728.195.506
Non-Controlling Interests		-	-
TOTAL LIABILITIES AND EQUITY		10.116.135.269	3.694.706.552

*The attached footnotes constitute an integral part of these consolidated financial statements.*

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE PERIOD JANUARY 1–DECEMBER 31, 2022**  
**CONSOLIDATED STATEMENT OF PROFIT OR LOSS**

(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)

Type of Financial Statement	Footnote No	Current Period	Previous Period
		Audited	Audited
Period		Consolidated January, 1- December 31, 2022	Consolidated January, 1- December 31, 2021
Revenue	4,23	20.434.426.246	9.308.745.555
Cost of Sales	4,23	(18.791.629.676)	(8.785.308.210)
<b>GROSS PROFIT/LOSS</b>		<b>1.642.796.570</b>	<b>523.437.345</b>
General Administrative Expenses	24	(114.526.085)	(41.266.820)
Marketing Expenses	24	(387.668.802)	(140.909.095)
Research and Development Expenses	24	(175.049)	(20.235)
Other Operating Income	25	1.496.625.136	675.096.205
Other Operating Expenses	25	(1.006.671.167)	(266.228.816)
<b>OPERATING PROFIT/LOSS</b>		<b>1.630.380.603</b>	<b>750.108.584</b>
Income from Investing Activities	25	81.544.984	4.387.105
Expenses from Investment Activities	25	(3.449.988)	-
Cancelled Impairment Earnings and Losses Determined as per TFRS 9	25	(3.232.945)	(638.241)
Shares from Profits (Losses) of Investments Valued by Equity Method	12	3.531.488	1.200.919
<b>OPERATING PROFIT/LOSS BEFORE FINANCE EXPENSES</b>		<b>1.708.774.142</b>	<b>755.058.367</b>
Finance Income	27	848.097.305	581.329.612
Finance Expenses	27	(1.740.153.991)	(1.150.381.668)
<b>PROFIT/LOSS BEFORE TAX FROM CONTINUING OPERATIONS</b>		<b>816.717.456</b>	<b>186.006.311</b>
<b>Tax Expense/Income from Continuing Operations</b>		<b>(103.832.245)</b>	<b>(46.411.055)</b>
Tax Expense/Income for the Period	28	(108.883.709)	(17.614.285)
Deferred Tax Expense/Income	28	5.051.464	(28.796.770)
<b>PROFIT (LOSS) FOR THE PERIOD</b>		<b>712.885.211</b>	<b>139.595.256</b>
<b>Distribution of the Profit (Loss) for the Period</b>		<b>712.885.211</b>	<b>139.595.256</b>
Non-Controlling Interests		-	-
Parent Company Shares		712.885.211	139.595.256
<b>Earnings (Losses) per Share</b>		<b>3,9174</b>	<b>0,7376</b>
Earnings per Share from Continuing Operations		3,9174	0,7376

The attached footnotes constitute an integral part of these consolidated financial statements.

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE PERIOD JANUARY 1–DECEMBER 31, 2022**  
**CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME**  
*(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)*

		<b>Current Period</b>	<b>Previous Period</b>
		<i>Audited</i>	<i>Audited</i>
<b>Type of Financial Statement</b>	<b>Footnote No</b>	<b>Consolidated</b>	<b>Consolidated</b>
<b>Period</b>		<b>January, 1- December 31, 2022</b>	<b>January, 1- December 31, 2021</b>
<b>Profit For the Period</b>		<b>712.885.211</b>	<b>139.595.256</b>
<b>Other Income not to be Reclassified to Profit or Loss</b>		<b>1.469.226.644</b>	<b>218.776.529</b>
Increases/Decreases in Tangible Assets Due to Revaluation		1.479.172.813	219.518.730
Revaluation Gains (Losses) on Defined Benefit Plans		(9.809.939)	(691.637)
Shares of Other Comprehensive Income from Investments Valued by the Equity Method Not to be Classified in Profit or Loss		(136.230)	(50.564)
<b>Taxes Related to Other Comprehensive Income not to be Reclassified to Profit or Loss</b>		<b>(146.330.871)</b>	<b>(28.559.226)</b>
Revaluation Gains (Losses) on Defined Benefit Plans, Tax Effect		2.256.286	159.077
Increases/Decreases in Tangible Assets Due to Revaluation, Tax Effect		(148.618.490)	(28.729.933)
Shares of Other Comprehensive Income from Investments Valued by the Equity Method Not to be Classified in Profit or Loss, Tax Effect		31.333	11.630
<b>Other Income to be Reclassified to Profit or Loss</b>		<b>88.887.585</b>	<b>40.639.851</b>
Foreign Currency Exchange Differences		88.887.585	40.639.851
<b>Taxes Related to Other Comprehensive Income to be Reclassified to Profit or Loss</b>		<b>-</b>	<b>-</b>
Deferred Tax Expense/Income		-	-
<b>OTHER COMPREHENSIVE INCOME (EXPENSES)</b>		<b>1.411.783.358</b>	<b>230.857.154</b>
<b>TOTAL COMPREHENSIVE INCOME (EXPENSES)</b>		<b>2.124.668.569</b>	<b>370.452.410</b>
<b>Distribution of Total Comprehensive Income</b>		<b>2.124.668.569</b>	<b>370.452.410</b>
Non-Controlling Interests		-	-
Parent Company Shares		2.124.668.569	370.452.410

*The attached footnotes constitute an integral part of these consolidated financial statements.*

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE PERIOD JANUARY 1–DECEMBER 31, 2022**  
**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
*(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)*

	Footnote No	Paid-in Capital	Repurchased Shares	Share Issuance Premiums/ Discounts	Other Accumulated Comprehensive Income or Expenses not to be Reclassified to Profit or Loss			Other Accumulated Comprehensive Income or Expenses to be Reclassified to Profit or Loss	Accumulated Profits			Equities
					Increases/ Decreases in Tangible Assets Due to Revaluation	Revaluation Gains (Losses) on Defined Benefit Plans	Shares of Other Comprehensive Income from Investments Valued by the Equity Method Not to be Classified in Profit and Loss	Foreign Currency Exchange Differences	Reserves on Retained Earnings	Retained Profits/ Losses	Net Profit/ Loss for the Period	
<b>Balances as of 01.01.2021</b>		<b>84.500.000</b>	-	<b>57.194.029</b>	<b>62.149.360</b>	<b>(705.523)</b>	-	<b>15.353.588</b>	<b>7.726.207</b>	<b>115.008.531</b>	<b>43.282.290</b>	<b>384.508.482</b>
Transfers									2.375.830	40.906.460	(43.282.290)	-
Total Comprehensive Income (Expenses)					190.788.797	(532.560)	(38.934)	40.639.851			139.595.256	370.452.410
- Profit (Loss) for the Period											139.595.256	139.595.256
- Other Comprehensive Income (Expenses)					190.788.797	(532.560)	(38.934)	40.639.851				230.857.154
Capital Increase		106.470.000		(41.925.000)						(64.545.000)		-
Increase (Decrease) Due to Share Buyback Transactions			(26.765.386)						26.765.386	(26.765.386)		(26.765.386)
<b>Balances as of 31.12.2021</b>	<b>22</b>	<b>190.970.000</b>	<b>(26.765.386)</b>	<b>15.269.029</b>	<b>252.938.157</b>	<b>(1.238.083)</b>	<b>(38.934)</b>	<b>55.993.439</b>	<b>36.867.423</b>	<b>64.604.605</b>	<b>139.595.256</b>	<b>728.195.506</b>
<b>Balances as of 01.01.2022</b>		<b>190.970.000</b>	<b>(26.765.386)</b>	<b>15.269.029</b>	<b>252.938.157</b>	<b>(1.238.083)</b>	<b>(38.934)</b>	<b>55.993.439</b>	<b>36.867.423</b>	<b>64.604.605</b>	<b>139.595.256</b>	<b>728.195.506</b>
Transfers									3.952.224	135.643.032	(139.595.256)	-
Total Comprehensive Income (Expenses)					1.330.554.323	(7.553.653)	(104.897)	88.887.585			712.885.211	2.124.668.569
- Profit (Loss) for the Period											712.885.211	712.885.211
- Other Comprehensive Income (Expenses)					1.330.554.323	(7.553.653)	(104.897)	88.887.585				1.411.783.358
Increase (Decrease) Due to Share Buyback Transactions			(37.802.377)						37.802.377	(37.802.377)		(37.802.377)
<b>Balances as of 31.12.2022</b>	<b>22</b>	<b>190.970.000</b>	<b>(64.567.763)</b>	<b>15.269.029</b>	<b>1.583.492.480</b>	<b>(8.791.736)</b>	<b>(143.831)</b>	<b>144.881.024</b>	<b>78.622.024</b>	<b>162.445.260</b>	<b>712.885.211</b>	<b>2.815.061.698</b>

*The attached footnotes constitute an integral part of these consolidated financial statements*

**ULUSOY UN SANAYİ VE TİCARET ANONİM ŞİRKETİ**  
**FOR THE PERIOD JANUARY 1–DECEMBER 31, 2022**  
**CONSOLIDATED STATEMENT OF CASH FLOW**

(All amounts are expressed in Turkish lira (TRY) unless otherwise stated.)

Type of Financial Statement	Footnote No	Current Period	Previous Period
		Audited	Audited
Period		Consolidated	Consolidated
		January, 1-December 31, 2022	January, 1-December 31, 2021
<b>Cash Flows from Operating Activities</b>		<b>1.028.706.227</b>	<b>227.690.083</b>
Profit (Loss) for the Period		712.885.211	139.595.256
- Profit (Loss) for the Period from Continuing Operations	22	712.885.211	139.595.256
Adjustments Related to Net Profit (Loss) Reconciliation for the Period		152.274.616	(38.812.811)
- Adjustments Related to Depreciation and Amortization Expenses	16,17,18	52.055.922	10.807.688
- Adjustments Related to Provisions	8-20	3.914.470	(25.046.349)
- Adjustments Related to Interest Income (Expenses)	27	(56.405.999)	(81.941.777)
- Adjustments Related to Tax (Income) Expenses	28	152.710.223	57.367.627
Changes in Operational Capital		163.546.400	126.907.638
- Adjustments Related to Decreases (Increases) in Trade Receivables	8,30	(2.210.866.526)	69.430.651
- Adjustments Related to Decreases (Increases) in Other Receivables Related to Operations	9,30	(25.994.942)	(146.153.544)
- Adjustments Related to Increases (Decreases) in Inventories	11	(417.343.713)	(309.051.294)
- Adjustments Related to Increases (Decreases) in Trade Payables	8,30	2.404.783.480	644.034.786
- Adjustments Related to Increases (Decreases) in Other Payables Related to Operations	9,30	345.077.533	65.175.818
- Adjustments Related to Other Increases (Decreases) in Operational Capital		67.890.568	(196.528.779)
<b>Cash Flows from Investing Activities</b>		<b>(275.388.285)</b>	<b>(126.949.960)</b>
Cash Inflows from Sale of Tangible and Intangible Assets		22.197.908	2.969.922
- Cash Inflows from Sale of Tangible Assets	17	22.197.908	2.969.922
Cash Outflows to Purchase of Tangible and Intangible Assets		(294.432.977)	(102.471.159)
- Cash Outflows to Purchase of Tangible Assets	17	(291.457.891)	(99.777.998)
- Cash Outflows to Purchase of Intangible Assets	18	(2.975.086)	(2.693.161)
Cash Outflows from Derivative Instruments		(4.087.290)	(134.700.859)
Dividends Received	13	934.074	782.136
Increase of Capital	22	-	106.470.000
<b>Cash Flows from Financing Activities</b>		<b>178.598.277</b>	<b>29.675.814</b>
Cash Inflows from Borrowing	7	3.006.330.351	630.940.204
- Cash Inflows from Loans		3.006.330.351	630.940.204
Cash Outflows Related to Debt Repayments		(2.408.960.727)	(462.205.227)
- Cash Outflows Related to Loan Repayments	7	(2.408.960.727)	(462.205.227)
Cash Outflows Related to Debt Payments Arising from Lease Contracts		(4.431.732)	(2.456.904)
Paid Interest	27	(495.031.102)	(152.788.825)
Interest Earned	27	80.691.487	16.186.566
<b>Net Increases (Decreases) in Cash and Cash Equivalents Before the Effect of Foreign Currency Exchange Differences</b>		<b>931.916.219</b>	<b>130.415.937</b>
The Effect of Foreign Currency Exchange Differences on Cash and Cash Equivalents		88.887.585	40.639.851
<b>Net Increases (Decreases) in Cash and Cash Equivalents</b>		<b>1.020.803.804</b>	<b>171.055.788</b>
<b>Cash and Cash Equivalents at the Beginning of the Period</b>	5	<b>498.900.970</b>	<b>327.845.182</b>
<b>Cash and Cash Equivalents at the End of the Period</b>	5	<b>1.519.704.774</b>	<b>498.900.970</b>

The attached footnotes constitute an integral part of these consolidated financial statements.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 1- GROUP'S ORGANIZATION AND FIELD OF ACTIVITY**

Ulusoy Un Sanayi ve Ticaret Anonim Şirketi ("Company"); was established in 1989 to manufacture, trade, import and export all kinds of foodstuffs such as flour, semolina, pasta and biscuits, from cereals and legumes.

The head office address of the Company is Denizevler Mahallesi Alaçam Caddesi Blok No:42 Interior Door No:1 Atakum / Samsun. The branch information of the Company is as follows:

Branch name	Branch Address
Istanbul Branch	Levent Mahallesi Şener Sokak No:5 Beşiktaş / İstanbul
Kirazlık Branch	Şabanoğlu Mahallesi Atatürk Bulvarı No:272 Tekkeköy / Samsun
Çorlu Branch	Hıdırağa İstasyon No:20/A Çorlu / Tekirdağ
Ellinci Yıl Branch	Çiftlik OSB Mahallesi 3. Cadde No:12 Tekkeköy / Samsun
Samsun Free Zone Branch	Liman SB Mahallesi 1. Cadde Sasbaş Ofisler Apt. No:36/17 İlkadım / Samsun

The registered capital ceiling of the Company is 422,500,000 TL. The registered capital ceiling permission granted by the Capital Markets Board ("CMB") is valid for the years 2020 – 2024 (5 Years).

As of 31 December 2022, the issued capital of the Company is 190.970.000 TL. (One hundred ninety-one million nine hundred and seventy thousand Turkish Liras) This capital is divided into 190.970.000 shares, each of which has a nominal value of 1 TL, 22.035.000 Group A, 14.690.000 Group B and 154.245.000 Group C. A and B Group shares are registered shares, C Group shares traded in Borsa İstanbul are bearer shares, and other Group C shares are registered shares. In the election of the Board of Directors of Group A shares; Group A and B shares have privileges in voting at the General Assembly, and with the exception of independent members, if the Board of Directors consists of five members, at least two members; if it consists of six or seven members, at least three members; If it consists of eight or nine members, at least four members, if it consists of ten or eleven members, at least five members are selected from among the candidates nominated by the majority of Group (A) shareholders. (A) Group shareholders or their proxies present at the Ordinary and Extraordinary General Assembly meetings have 15 (fifteen) voting rights for each share, (B) Group shareholders or their proxies have 10 (ten) voting rights for each share and (C) Group shareholders or their proxies have 1 (one) voting right for each share.

As of 31 December 2022, the number of personnel employed within the Group is 791 (31 December 2021: 381 personnel).



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 1 - GROUP'S ORGANIZATION AND FIELD OF ACTIVITY (Cont.)**

The Group's capital distribution as of December 31, 2022 is as follows:

Shareholders	Number of Shares	Group	Percentage (%)	Amount
Nevin Ulusoy	9.548.501	A	5,00	9.548.501
	2.938.000	B	1,54	2.938.000
	23.589.237	C	12,35	23.589.237
	<b>36.075.738</b>		<b>18,89</b>	<b>36.075.738</b>
Onur Erhan Ulusoy	1.469.000	A	0,77	1.469.000
	3.407.000	B	1,78	3.407.000
	13.024.001	C	6,82	13.024.001
	<b>17.900.001</b>		<b>9,37</b>	<b>17.900.001</b>
Eren Günhan Ulusoy	11.017.499	A	5,77	11.017.499
	8.345.000	B	4,37	8.345.000
	52.380.358	C	27,43	52.380.358
	<b>71.742.857</b>		<b>37,57</b>	<b>71.742.857</b>
Mithat Denizcigil	215.518	C	0,11	215.518
	<b>215.518</b>		<b>0,11</b>	<b>215.518</b>
Kâmil Adem	60.887	C	0,03	60.887
	<b>60.887</b>		<b>0,03</b>	<b>60.887</b>
Open To Public	<b>64.975.000</b>	C	<b>34,02</b>	<b>64.975.000</b>
<b>Total</b>	<b>190.970.000</b>		<b>100,00</b>	<b>190.970.000</b>

**Subsidiaries**

The Company's its subsidiaries in the scope of consolidation as of December 31, 2022 and December 31, 2021 are as follows;

Subsidiaries	Subsidiaries Percent (%)	
	December 31, 2022	December 31, 2021
Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.	100	100
GK Tarım Ürünleri Lisanslı Depoculuk A.Ş. (*)	-	100
Rolweg SA	100	100
Alfaway Gıda Sanayi ve Ticaret A.Ş.	100	100
Söke Değirmencilik Sanayi ve Ticaret A.Ş.	100	-

(\*) GK Tarım Ürünleri License Depoculuk A.Ş., with the General Assembly decision dated 6 December 2022, registered on 9 December 2022, merged with Uludaş Tarım Ürünleri License Warehouse San. ve Tic. Inc. and dissolved.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

---

### **FOOTNOTE 1 - GROUP'S ORGANIZATION AND FIELD OF ACTIVITY (Cont.)**

#### **Disclosures Concerning the Subsidiaries' Field of Activity**

##### ***Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.***

Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş. ("Uludaş") was established on February 27, 2015 to provide licensed warehousing services for storage of agricultural products under healthy conditions.

The headquarters of Uludaş is located in Sabanoglu District Ataturk Boulevard No:180/1 Tekkeköy, Samsun. It has 24 personnel as of December 31, 2022. (December 31, 2021: 25 personnel)

As of 31 December 2022, its capital is 27,000,000 TL (31 December 2021: 25,000,000 TL) and it has no outstanding capital.

##### ***Rolweg SA***

Rolweg SA was established on 15 March 2018 to trade grain with a capital of 1,000,000 Swiss Francs (CHF). 100% of Rolweg's capital belongs to Ulusoy Un Sanayi ve Ticaret A.Ş. The head office address of Rolweg SA is Rue du Nant6, 1207 Geneva Switzerland. The capital of Rolweg SA, which was 7,500,000 Swiss Francs as of 31 December 2021, was increased by 2,500,000 Swiss Francs to 10,000,000 CHF by the Board of Directors Decision dated 15 August 2022.

##### ***Alfaway Gıda Sanayi ve Ticaret A.Ş.***

Alfaway Gıda Sanayi ve Ticaret A.Ş. ("Alfaway") was established on September 24, 2019 to manufacture, wholesale and retail purchase, sale and distribution, import and export of all kinds of foodstuffs. The head office address of Alfaway is Kılıçdede Mahallesi Ülkem Sokak Niş Borkont Business Center No:8 A-Block Floor:6 Flat:56-57 İlkadım/Samsun.

As of 31 December 2022 and 31 December 2021, its capital is 5,000,000 TL. As of 31 December 2022, the number of employed personnel is 71. (31 December 2021: 69 people)

##### ***Söke Değirmencilik Sanayi ve Ticaret A.Ş.***

Söke Değirmencilik Sanayi ve Ticaret A.Ş. ("Söke Değirmencilik") was established in 1963 in Söke. Söke Değirmencilik operates in flour production. Söke Değirmencilik generally produces flour and flour products for the Turkish market. Production is carried out in 2 locations, one in Söke and one in Ankara. The address and main activity center of Söke Değirmencilik is Sazlı Mahallesi Fabrika Sokak No:2 Söke/Aydın. The address of the Ankara branch of Söke Değirmencilik is Ahi Evranosb Mahallesi Kazakhstan Caddesi No:8 Sincan/Ankara.

The capital of Söke Değirmencilik, which was TL 87,633,475 as of December 31, 2021, was increased from TL 87,633,475 to TL 309,000,000 with the General Assembly Decision registered on September 29, 2022. (See: Footnote 34) As of 31 December 2022, the number of personnel employed is 337. (31 December 2021:323 personnel)

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

---

### **FOOTNOTE 2- GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS**

#### **2.1 Guidelines for Presentation**

The consolidated financial statements of the Group are in accordance with the provisions of the Capital Markets Board's Communiqué Serial II, 14.1 numbered "Principles of Financial Reporting in the Capital Markets" ("Communiqué") published in the Official Gazette dated 13 June 2013 and numbered 28676. It has been prepared on the basis of Turkish Financial Reporting Standards ("TFRS") and its annexes and comments, in compliance with the international standards published by the Accounting and Auditing Standards Authority ("KGK"). TFRS is updated through communiqués to ensure parallelism with the changes in International Financial Reporting Standards ("TFRS").

The consolidated financial statements are presented in accordance with the formats specified in the Financial Statement Examples and User Guide published by the KGK ("Announcement on TMS Taxonomy") and the CMB.

POA made a statement on January 20, 2022, in order to eliminate the hesitations about whether the companies applying Turkish Financial Reporting Standards (TFRS) will apply TAS 29 Financial Reporting in High Inflation Economies in the 2021 financial reporting period. Accordingly, it has been stated that the enterprises applying TFRS do not need to make any adjustments within the scope of TAS 29 Financial Reporting in High Inflation Economies ("TAS 29"), and no new statement has been made by the KGK on the application of TAS 29 afterwards. Considering that no new disclosure has been made as of the date these consolidated financial statements were prepared, no inflation adjustment was made in accordance with TAS 29 while preparing the consolidated financial statements as of 31 December 2022.

#### **Valid and reporting currency**

The Group's consolidated financial statements for the period are presented in TRY, the functional and presentation currency. The assets and liabilities in the financial statements of the subsidiary operating in the foreign country, prepared in USD, were converted into TRY based on the exchange rate on the date of the balance sheet, whereas its income and expenses were converted based on the average exchange rate. The exchange differences arising from the use of the closing and average exchange rates are kept track of under the changes in foreign exchange rates.

#### **Netting/Offsetting**

Financial assets and liabilities are presented as net values in cases where there is a legal claim or an intention to evaluate the assets and liabilities as net values, or where the acquisition of the assets and the fulfillment of the liabilities succeed each other.

#### **Approval of Consolidated Financial Statements**

The consolidated financial statements prepared as of 31 December 2022 were approved by the Company Management on 10 March 2023. The General Assembly has the authority to change the consolidated financial statements after they are published.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

**2.1 Guidelines for Presentation (Cont.)**

**Consolidation Guidelines**

**a) Subsidiaries**

Consolidated financial statements include the financial statements of the Company and its subsidiaries. The Company is deemed to have control over its subsidiaries if it meets the following conditions:

- Having influence over the investee;
- Being open or entitled to the variable returns to be obtained from the investee;
- Being able to exercise its control over the returns.

In cases where the company does not have the majority voting right over the investee, it has controlling interest in the investee if it has sufficient voting rights to direct the activities of the relevant investment alone.

The company considers all relevant events and conditions, including the following, in assessing whether the majority of the votes in the relevant investee is sufficient to have controlling interest:

- Comparing the voting right of the company with the voting rights of other shareholders;
- Potential voting rights owned by the company and other shareholders;
- Rights arising from other contracts;
- Other events and conditions that may show whether the Company currently has interest in managing the relevant activities (including voting at the general assembly meetings in previous periods) in cases where a decision is required.

Should any situation or event that may cause change in any of the abovementioned criteria occur, the Company reevaluates whether it has controlling interest in its investee.

Inclusion of a subsidiary in the scope of consolidation starts with the Company gaining control over the subsidiary and ends with the loss of this control. Income and expenses of the subsidiaries acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date of acquisition to the date of disposal.

The Subsidiaries' statements of financial position and statements of profit or loss and other comprehensive income were consolidated using the full consolidation method.

Each item of consolidated profit or loss and other comprehensive income belongs to the parent company shareholders and non-controlling interests. Even if non-controlling interests result in red balance, total consolidated profit or loss and other comprehensive income of subsidiaries are transferred to parent company shareholders and non-controlling interests.

Where necessary, adjustments regarding the accounting policies were made in the financial statements of the subsidiaries to ensure uniformity with the accounting policies followed by the Group.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.1 Guidelines for Presentation (Cont.)

##### Consolidation Guidelines (Cont.)

##### a) Subsidiaries (Cont.)

All intragroup assets and liabilities, equity, income and expenses and cash flows from transactions between Group companies are eliminated in the consolidation process.

Shareholding percentages of the subsidiaries controlled by the Company as of December 31, 2022 and December 31, 2021 are as follows:

Subsidiaries	Shareholding Percentages (%)	
	December 31,	December 31,
	2022	2021
Uludaş Tarım Ürünleri Lisanslı Depoculuk San. ve Tic. A.Ş.	100	100
GK Tarım Ürünleri Lisanslı Depoculuk A.Ş. (*)	-	100
Rolweg SA	100	100
Alfaway Gıda Sanayi ve Ticaret A.Ş.	100	100
Söke Değirmencilik Sanayi ve Ticaret A.Ş. (**)	100	-

(\*) GK Tarım Ürünleri License Depoculuk A.Ş., with the General Assembly decision dated 6 December 2022, registered on 9 December 2022, merged with Uludaş Tarım Ürünleri License Warehouse San. ve Tic. Inc. and dissolved.

(\*\*) With the decision of the Board of Directors dated January 11, 2022, the company became a subsidiary of Söke Değirmencilik Sanayi ve Ticaret A.Ş. its controlling shareholder, Moms Kitchen International S.a.r.l. and other partners, Söke Değirmencilik Sanayi ve Ticaret A.Ş. An agreement was reached for the purchase of all of its shares, to be paid 168.900.000 TL in cash on 11/01/2022 and 650,000 EUR on 11/01/2023, and the purchase agreement was signed. All of the shares of Söke Değirmencilik Sanayi ve Ticaret A.Ş. have been purchased by the Company.

##### b) Affiliates

Affiliates are accounted for using the equity method. These are entities in which the Group generally has between 20% and 50% of the voting rights or in which the Group has significant influence, but not control, over the company's operations.

Unrealized gains and losses on transactions between the Group and its Affiliates are eliminated to the extent of the Group's interest in the Affiliate. Equity method is discontinued if the carrying value of the investment in the Affiliate is zero or the Group's significant influence ceases, unless the Group has assumed any obligation or made a commitment accordingly. The carrying amount of the investment at the date that significant influence ceases is presented at its fair value after that date when the fair value can be reliably measured. As of 31 December 2022 and 31 December 2021, the shares in the Affiliate are shown below.

Affiliates	Shareholding Percentages (%)	
	December 31,	December 31,
	2022	2021
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş. ("Sasbaş")	17	17

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### **FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.2 New and Revised Standards and Interpretations**

##### **a) The new standards in force as of 31 December 2022 and the amendments and interpretations to the existing previous standards:**

##### **Amendments to TFRS 16 'Leases - COVID 19 Lease Concessions' extension of facilitating application**

As of March 2021, this change has been extended until June 2022 and is effective from April 1, 2021. Due to the COVID-19 outbreak, some privileges have been provided to tenants in rent payments. These concessions can take various forms, including suspending or deferring rental payments. With the amendment published in the TFRS 16 Leases standard, IASB introduced an optional facilitating practice for the lessees not to evaluate whether there is a change in the lease due to the concessions granted due to COVID-19 in the lease payments.

Lessees may choose to account for such lease concessions in accordance with the terms that would apply in the absence of a lease modification. This ease of application often causes the lease concession to be recognized as a variable lease payment during periods when the event or condition that triggers the reduction in lease payments occurs.

##### **Change in references to the conceptual framework (Amendments to TFRS 3)**

POA made changes to the TFRS Business Combinations standard in July 2020. The change was made with the intention of replacing the reference to the old version of the Conceptual Framework (1989 framework) with a reference to the current version (Conceptual Framework) released in March 2018, without materially changing the requirements of TFRS 3. However, a new paragraph has been added to TFRS 3 to define contingent assets that do not meet the recognition criteria at the acquisition date. The amendment is applied prospectively for annual accounting periods beginning on or after January 1, 2022.

##### **Disadvantageous contracts-Costs to fulfill the contract (Amendments to TAS 37)**

POA made changes to the TFRS Business Combinations standard in July 2020. The change was made with the intention of replacing the reference to the old version of the Conceptual Framework (1989 framework) with a reference to the current version (Conceptual Framework) released in March 2018, without materially changing the requirements of TFRS 3. However, a new paragraph has been added to TFRS 3 to define contingent assets that do not meet the recognition criteria at the acquisition date. The amendment is applied prospectively for annual accounting periods beginning on or after January 1, 2022.

##### **Adaptation for intended use (Amendments to TAS 16)**

In July 2020, POA made changes to TAS 16 Tangible Fixed Assets standard. With the amendment, companies do not allow revenues from the sale of manufactured products to be deducted from the cost of the tangible asset item, while making a tangible asset fit for its intended use. Companies will now recognize such sales revenue and related costs in profit or loss. The amendment is applicable for annual accounting periods beginning on or after January 1, 2022.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.2 New and Revised Standards and Interpretations (Cont.)

##### b) a) The new standards in force as of 31 December 2022 and the amendments and interpretations to the existing previous standards (Cont.)

##### Annual Improvements - 2018-2020 Period

"Annual Improvements to TFRS standards / 2018-2020 Period" was published by the POA in July 2020, including the following changes:

- *TFRS 1- First Application of International Financial Reporting Standards – Partner as First Implementer*: The amendment allows a subsidiary to measure accumulated currency translation differences using amounts reported by the parent. The amendment also applies to the subsidiary or joint venture.
- *TFRS 9 Financial Instruments - Fees considered in the 10% test for derecognition of financial liabilities*: The amendment clarifies the fees that an entity considers when assessing whether new or modified financial liability terms differ materially from the original financial liability terms. These fees include only fees paid or received between the borrower and the lender, including fees paid by the parties on behalf of each other.
- *TAS 41 Agricultural Activities – Taxes in determining fair value*: With the amendment, the provision in TAS 41 paragraph 22 that companies do not consider cash flows for taxation in determining the fair value of their assets within the scope of TAS 41 has been removed.

All of the improvements made will be applied for annual accounting periods beginning on or after January 1, 2022. Early application is permitted.

##### b) Standards and amendments published but not yet effective as of 31 December 2022

##### TFRS 17 – New insurance contracts standard

In February 2019, POA published TFRS 17, a comprehensive new accounting standard covering recognition and measurement, presentation and disclosure for insurance contracts. TFRS 17 introduces a model that provides both the measurement of liabilities arising from insurance contracts with current balance sheet values and the recognition of profits throughout the period in which the services are provided. TFRS 17 will be applied for annual accounting periods beginning on or after 1 January 2023. Early application is permitted.

##### TAS 12, Amendment to deferred tax on assets and liabilities arising from a single transaction

Effective for annual reporting periods beginning on or after 11 January 2023. These amendments require deferred tax recognition on transactions that cause equal amounts of taxable and deductible temporary differences when first recognized by companies.

##### Narrow changes in TMS 1, Application Statement 2, and TAS 8

Effective for annual reporting periods beginning on or after 1 January 2023. These changes are intended to improve accounting policy disclosures and help financial statement users distinguish between changes in accounting estimates and changes in accounting policies.

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### **FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.2 New and Revised Standards and Interpretations (Cont.)**

##### **b) Standards and amendments published but not yet effective as of 31 December 2022 (Cont.)**

##### **Classification of liabilities as short and long term (Amendments in TAS 1)**

In January 2021, POA made changes to the "TAS 1 Presentation of Financial Statements" standard. These amendments, which are effective for the annual reporting periods beginning on or after January 1, 2024, clarify the criteria for long and short term classification of liabilities. Changes made should be applied retrospectively according to TAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors". Early application allowed

##### **TFRS 16, Sale and leaseback transactions**

Effective for annual reporting periods beginning on or after 1 January 2024. These changes include the sale and leaseback requirements in TFRS 16 that describe how an entity accounts for a sale and leaseback transaction after the transaction date. Sales and leaseback transactions where some or all of the lease payments consist of variable lease payments that are not tied to an index or rate are likely to be affected.

#### **2.3 Changes in Accounting Policies**

Accounting policy changes resulting from the first application of a new TFRS, in accordance with the transitional provisions of the said TFRS, if any; If there is no transitional provision or if there is an optional material change in the accounting policy, it is applied retrospectively and the prior period consolidated financial statements are restated.

#### **2.4 Comparative Information and Restatement of Prior Period Consolidated Financial Statements**

The accompanying consolidated financial statements are prepared comparatively with the previous period in order to determine the consolidated financial position, performance and cash flow trends of the Group. When the presentation or classification of the items in the consolidated financial statements changes, in order to ensure comparability, the previous period's consolidated financial statements are reclassified accordingly and explanations are made regarding these issues.

#### **2.5 Changes and Errors in Accounting Estimates**

If the effect of a change in an accounting estimate relates to only one period, in the current period in which the change is made; If it is related to future periods, it is reflected in the consolidated financial statements both in the future and in the future period, to be taken into account in determining the net profit or loss for the period.

The amount of correction of an error is considered retrospectively. An error is corrected by restating the comparative amounts for previous periods in which it arose or, when it occurs before the next reporting period, by restating the retained earnings account for that period. If the rearrangement of the information causes an excessive cost, the comparative information of the previous periods is not rearranged, and the retained earnings account of the next period is rearranged with the cumulative effect of the error before the said period starts.



## ULUSOY UN SANAYİ VE TİCARET A.Ş.

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.6 Summary of Significant Accounting Policies

##### Revenue

Revenues are recognized on an accrual basis at the time when deliveries are made, the amount of revenue can be measured reliably and it is probable that the economic benefits associated with the transaction will flow to the Group at the fair value of considerations that is or can be received. Net sales represent the sale price of goods sold net of the price of returned goods, discounts, commissions and related taxes. The Group recognizes the revenues based on the following conditions:

- (a) identification of customer contracts,
- (b) identification of performance liabilities,
- (c) determination of transaction price in the contract,
- (d) sorting of the prices related to the performance liabilities,
- (e) recognition of revenue when the performance liabilities are fulfilled.

The Group solely records the revenues earned from the customers when the conditions mentioned below are met:

- (a) If the contracting parties have approved the contract (in writing, verbally or by other usual business practices) and undertaken to fulfill the individual liabilities specified in the contract,
- (b) If the Group can define its rights and liabilities of both parties in relation to the product or service,
- (c) If the Company can stipulate terms of payment for the products and services,
- (d) If the contract has the characteristics of a business transaction,
- (e) The Group is likely to collect the prices of the goods and services provided to the customers.
- (f) The Company should take into account only the solvency and willingness-to-pay of the customer on the due date when assessing the collectability of the mentioned fee.

The Group's revenues arise from sale of wheat, corn, flour, bran, razmol and ear.

##### Investment Properties

Lands or buildings or parts thereof held (by the owner or by the lessee depending on the financial lease contract) to obtain rental income or appreciation gains or both instead of being used for production or procurement of goods and services or for administrative purposes or being sold in the ordinary course of business are classified as investment properties.

An investment property is recognized as an asset in the case that the future economic benefits associated with it are likely to flow to the company and its cost can be reliably measured. Investment properties are reflected in the consolidated financial statements based on their revalued amount. Appreciation gains or impairment losses based on valuation reports are recognized in profit or loss in the period in which they arise.

Investment properties are reviewed to determine a potential impairment, and the book value of an investment property is reduced to the recoverable value by setting aside a provision in the event of the book value exceeding its recoverable value.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)****2.6 Summary of Significant Accounting Policies (Cont.)****Tangible Assets**

The Group's tangible assets, such as its underground and ground plants and fixtures, are shown as cost values, including the costs incurred to make them available for use, net of accumulated depreciation and accumulated impairment. Lands, buildings, machinery, facilities, equipment and vehicles are included in the consolidated financial statements based on the revaluation model and the value differences are reported among the equities under the revaluation reserve and in the comprehensive income statement for the relevant period. In the case that an item of property, plant and equipment is sold, the cost and accumulated depreciation of this item is removed from the relevant accounts and the arising profit or loss is recognized in the profit or loss statement. Assets other than plots of land are subjected to depreciation based on the rate of depreciation designated according to the asset's useful life.

The expenses arising from the replacement of any part of the tangible assets can be capitalized along with the maintenance and repair costs if they increase the future economic benefit of the asset. All other expenses are recognized as expense items in the income statement. In case of conditions suggesting an impairment in an item of property, plant and equipment, a review is carried out and the book value of the item is reduced to the recoverable value by setting aside a provision if its book value exceeds its recoverable value.

If the book value of the item of tangible assets increases as a result of revaluation, this increase is directly included in the consolidated financial statement under the name "revaluation reserve" in the equity account group. However, any increase in value as a result of revaluation is recognized as revenue in consolidated financial statements to the extent that the same asset reverses the revaluation impairment previously recognized as an expense. If the book value of the asset decreases as a result of the revaluation, this impairment is recognized as an expense in the financial statements. However, if a revaluation reserve has been established regarding the asset, the impairment is first removed from that account. In the event that the impairment exceeds the revaluation reserve, the exceeding part is associated with the income statement.

The estimated economic lives of tangible assets are as follows:

<b>Type of Tangible Assets</b>	<b>Estimated Economic Life</b>
Underground and Ground Plants	25-50 Years
Buildings	25-50 Years
Facilities, Machinery and Equipment	4-50 Years
Vehicles	2-15 Years
Fixtures	3-50 Years

Depreciation methods, useful lives and residual values are reviewed as of each reporting date and adjusted when necessary.

**Intangible Assets Other than Goodwill**

Intangible assets other than goodwill are recorded at their acquisition cost and depreciated based on the rates determined according to the useful life of the asset.

<b>Type of Intangible Assets</b>	<b>Estimated Economic Life</b>
Rights	3-15 Years

## **ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### **FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

#### **2.6 Summary of Significant Accounting Policies (Cont.)**

##### **Impairment of assets**

For financial assets that are not recognized in profit or loss, an assessment is made, at the end of each reporting period, as to whether there is any objective evidence that they are impaired.

Objective evidence of impairment of financial assets includes:

- significant financial difficulty of the issuer or obligor;
- the lender granting to the Group a concession that the lender would not otherwise consider;
- it becoming probable that the borrower or issuer will enter bankruptcy;
- a default or delinquency of these persons;
- the disappearance of an active market for a financial asset or
- observable data indicating that there is a measurable decrease in the estimated future cash flows from the financial asset.

The fair value of an investment based on equity shares dropping significantly or permanently below its cost value is also objective evidence of impairment.

##### **Borrowing costs**

In case of assets for which it takes considerable time to make them available for use and sale, the borrowing costs that can be directly associated with the purchase, construction or production of the asset are capitalized as an item of its cost until the asset is made available for use or sale. The borrowing costs that do not fall into this scope are recognized as expense in the period in which they are incurred. The Group recognizes all financing expenses in profit or loss in the period in which they are incurred.

##### **Inventories**

Inventories are valued at the lower of net realizable value or cost. The cost of inventories includes all purchasing costs and other costs incurred in bringing the inventories to their current state and location. Net realizable value is the estimated selling price in the ordinary course of business less the estimated cost of completion and the estimated cost of selling necessary to make the sale. Weighted average cost method is applied as inventory valuation method.

##### **Financial Assets**

###### Cash and Cash Equivalents

Cash and cash equivalent items include cash, demand deposits, term deposits (with a maturity less than three months) and other highly liquid short-term investments that are due in three months or less from the date of purchase, can be converted into cash immediately and have no risk of considerable change in value. The Group reviews its cash and cash equivalents for impairment using the expected credit loss model.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.6 The Summary of Important Accounting Policies (Cont.)

##### Financial Assets (Cont.)

###### Trade Receivables

Trade receivables resulting from the supply of products to the buyer are accounted for at the amortized value using the effective interest method of the amounts to be obtained in the following periods of the receivables recorded at the original invoice value. Short-term receivables with no specified interest rate are shown at the invoice amount unless the effect of the original effective interest rate is significant. If there is a situation that indicates that the amounts that must be paid cannot be collected, a provision is made for the estimated uncollectible amounts for trade receivables and recorded in the profit/loss account. The Group reviews its trade receivables for impairment using the expected credit loss model.

Following the provision for impairment, if all or part of the amount of the impaired receivable is collected, the collected amount is deducted from the provision for impairment and recorded in other income from main activities. Interest income/expenses related to commercial transactions and foreign exchange gains/losses are accounted for in the "Other Operating Income/Expense" account in the consolidated statement of profit or loss. The Group collects some of its receivables through factoring. The amounts that the factoring company undertakes the collection risk from the receivables subject to the factoring transaction are deducted from the relevant receivables accounts.

###### Derivative Instruments

Derivative instruments are initially recognized at their acquisition cost reflecting their fair value and measured at fair value in the periods following their initial recognition. While they provide effective economic protection against risks for the Company, they are recognized as derivative instruments for trade purposes in cases where they do not meet the necessary conditions from the perspective of hedge accounting and changes in their fair value are recognized in income statement.

##### Financial Liabilities

###### Financial Payables

Interest-bearing financial payables are initially recognized at fair value and subsequently measured using the effective interest rate method.

###### Trade and Other Payables

Trade and other payables are initially recognized at fair value and subsequently measured at amortized value using the effective interest rate method.

##### Effects of currency change

Transactions accounted in foreign currency (currencies other than TRY) in the Group's legal records are translated into Turkish Lira using the exchange rates on the date of the transaction. Foreign currency-linked assets and liabilities in the consolidated statement of financial position are translated into Turkish Lira using the exchange rates prevailing at the reporting date. Foreign exchange gains and losses arising from this translation and collections and payments of foreign currency transactions are included in the consolidated statement of profit or loss.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.6 The Summary of Important Accounting Policies (Cont.)

##### Earnings / (Loss) Per Share

Earnings per share / (loss) is calculated by dividing the net profit or loss for the period by the weighted average of the number of ordinary shares owned by the ordinary shareholders in the current period.

Companies in Türkiye can increase their capital by distributing shares (bonus shares) to their existing shareholders from retained earnings and equity inflation adjustment differences in proportion to their shares. When calculating earnings/(loss) per share, these bonus shares are counted as issued shares. Therefore, the weighted average of shares used in the calculation of earnings / (loss) per share is obtained by applying it retrospectively in terms of bonus shares.

##### Events after the reporting period

This refers to events, whether positive and negative for the company, which occur between the end of the reporting period and the date authorization is given for the publication of the consolidated statement of financial position. The two types of events after the reporting period are:

- New evidence related to events being present as of the end of the reporting period (events that require adjustment after the reporting period) and
- Evidence indicating that the events occurred after the reporting period (events that do not require adjustment after the reporting period).

If new evidence emerges that the events were present at the end of the reporting period, or that they occurred after the reporting period and thus require adjustment of consolidated financial statements, the Group adjusts them in accordance with the new situation. If the events do not require the financial statements to be adjusted, the Group provides explanations for these matters.

##### Related parties

The Group's shareholders, the companies owned by them, their managers and other persons and entities that are known to be related to them are defined as related parties in the attached consolidated financial statements. Related party refers to direct or indirect control of the Group, a right to have significant influence over the Group, or an affiliate, board member and general manager of the Group.

##### Taxation

Income tax expenses consist of the current tax and total deferred tax.

##### (i) Current tax

Current tax is the expected tax liability or tax claim over profit or loss that is subject to taxation within the current year, and includes the tax liability and related adjustment records from the previous years.

It is calculated based on the tax rates that are applicable or will almost definitely be in effect as of the end of the reporting period. Current tax assets and liabilities can be offset only when certain conditions are met.

## ULUSOY UN SANAYİ VE TİCARET A.Ş.

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.6 The Summary of Important Accounting Policies (Cont.)

##### Taxation (Cont.)

###### *(ii) Deferred tax*

Deferred tax is calculated using the liability method, based on the temporary differences between the recognized values of assets and liabilities in the consolidated financial statements and their tax values.

Deferred tax liabilities are calculated for all taxable temporary differences, whereas deferred tax assets resulting from deductible temporary differences are calculated on condition that the utilization of these differences to earn taxable profits in the future is highly likely.

##### Employee benefits

###### *(i) Short-term employee benefits*

Short-term employee benefit obligations are expensed as the related service is rendered. A liability is recognized for the amounts expected to be paid when the Group has a legal or constructive obligation to pay as a result of past service of its employees and the obligation can be estimated reliably.

###### *(ii) Other long-term employee benefits*

The provision for employment termination benefits represents the present value of the estimated future probable obligation of the Group in the event of the retirement of its employees on a 30-day basis. The provision for severance pay is calculated as if all employees will be subject to such a payment and is reflected in the consolidated financial statements on an accrual basis. The provision for severance pay has been calculated according to the severance pay ceiling announced by the Government.

As of 31 December 2022, the severance pay ceiling is exactly 19.982.83 TL (31 December 2021: 8.284.51 TL). The Group management has used some estimates in calculating the provision for employment termination benefits.

All actuarial gains and losses related to employment termination benefits are recognized in other comprehensive income.

##### Contingent Assets and Liabilities

According to TAS 37 "Provisions, Contingent Liabilities and Contingent Assets", the Group must have an existing statutory or implied liability arising from previous events, the outflow of resources involving economic benefits must be probable and the said liability must be able to be estimated in a reliable manner so that any provision amount can be included in the financial statements. In the event of such criteria not being met, the Group explains such issues in the relevant footnotes.

If the inflow of economic benefit becomes probable, explanations regarding the contingent asset are provided in the footnotes to the consolidated financial statements. If the inflow of economic benefit becomes definite, the asset and the associated income are recognized in the consolidated financial statements on the date of the change.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

**2.6 The Summary of Important Accounting Policies (Cont.)**

**Business Combinations**

Business acquisitions are accounted for using the purchase method. The consideration transferred in a business combination is measured at fair value; The consideration transferred is calculated as the sum of the acquisition-date fair value of the assets transferred by the acquirer, the liabilities assumed by the acquirer to the previous owners of the acquiree, and the equity interests issued by the acquirer. Acquisition-related costs are generally recognized as an expense when incurred.

The identifiable assets purchased and liabilities assumed are accounted for at their fair values at the date of purchase. The following are not accounted for as such:

- Deferred tax assets or liabilities or assets or liabilities related to employee benefits are calculated and accounted for in accordance with TAS 12 Income Tax and TAS 19 Employee Benefits standards, respectively,
- Obligations or equity instruments associated with the share-based payment agreements of the acquiree or the share-based payment agreements the Group has entered into to replace the share-based payment agreements of the acquiree are accounted for in accordance with TFRS 2 Share-based Payment Agreements at the date of acquisition, and
- Assets (or disposal groups) classified as held for sale in accordance with TFRS 5 Non-current Assets Held for Sale and Discontinued Operations are accounted for in accordance with the rules set out in TFRS 5.

Goodwill is the sum of the consideration transferred for the acquisition, the non-controlling interests, if any, and, if any, the fair value of the acquirer's previous equity interests in the acquiree in a business combination accomplished in stages, the sum of the fair value of the acquiree's identifiable assets at the acquisition date, and It is calculated as the amount exceeding the net amount of the identifiable liabilities assumed. If, after reassessment, the net amount of the identifiable assets of the acquired business and identifiable liabilities assumed at the acquisition date exceeds the sum of the transferred purchase price, the non-controlling interests in the acquired business and, if any, the fair value of the interests in the purchased business before the acquisition, this amount is negotiated. It is recognized directly in profit or loss as a gain from the acquisition.

Non-controlling interests, which represent the shareholder interests and give the owners a certain share of the net assets of the business in the event of liquidation, are initially measured either at their fair value or at the amounts of the identifiable net assets of the acquired business recognized at the rate of the non-controlling interests. The measurement basis is determined by each transaction. Other types of non-controlling interests are measured at fair value or, where applicable, using the method specified in another TFRS.

**FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)**

**2.6 The Summary of Important Accounting Policies (Cont.)**

**Business Combinations (Cont.)**

Where the consideration transferred by the Group in a business combination includes contingent consideration, the contingent consideration is measured at fair value at the acquisition date and included in the consideration transferred in the business combination. If an adjustment to the fair value of the contingent consideration is required as a result of additional information revealed during the measurement period, this adjustment is retroactively adjusted from goodwill. The measurement period is the period after the acquisition date during which the acquirer can adjust the temporary amounts recognized in the business combination. This period cannot be more than 1 year from the date of purchase.

Subsequent recognition of changes in the fair value of the contingent consideration that do not qualify as measurement period adjustments vary depending on the classification made for the contingent consideration. Contingent consideration classified as equity is not remeasured and the subsequent payment is recognized in equity.

In cases where the acquisition accounting for a business combination cannot be completed at the end of the reporting date at which the combination occurs, the Group reports the provisional amounts for items for which the accounting has not been completed. These provisional reported amounts are adjusted during the measurement period or an additional asset or liability is recognized to reflect new information about events and conditions that occurred at that date that may have an impact on the amounts recognized at the acquisition date.

Some assets and liabilities that were not previously recognized as assets and liabilities in the financial statements of the acquired business are recognized. As of the acquisition date, the identifiable assets, identifiable liabilities and minority interests of the acquired business are accounted for at their fair values. Related calculations are made according to some assumptions and evaluations.

**Goodwill**

The amount of goodwill arising from the acquisition is valued at the cost value at the acquisition date, after deducting the provisions for impairment, if any.

For impairment testing, goodwill is allocated to the Group's cash-generating units (or groups of cash-generating units) that expect to benefit from the synergies brought about by the merger.

The cash-generating unit to which the goodwill is allocated is tested for impairment annually. Where there are indications that the unit is impaired, impairment testing is performed more frequently. If the cash-generating unit's recoverable amount is less than its carrying amount, the impairment allowance is first set aside from the goodwill allocated to the unit, then the carrying amount of the assets in the unit is reduced. The impairment provision for goodwill is recognized directly in the consolidated statement of profit or loss and other comprehensive income. Provision for impairment of goodwill is not canceled in subsequent periods. During the sale of the relevant cash generating unit, the amount determined for goodwill is included in the calculation of profit/loss in the sale transaction.

Sometimes the acquirer makes a bargain purchase, which is a transfer that requires the acquisition-date net amount of identifiable assets acquired and identifiable liabilities assumed, measured in accordance with TFRS, usually at fair value at the acquisition date. is a business combination for which the value is exceeded. If the excess amount remains after the requirements of paragraphs 3 to 36 of TFRS 3 are applied, the acquirer recognizes the resulting gain in profit or loss at the acquisition date. That gain is attributed to the acquiring business.



## ULUSOY UN SANAYİ VE TİCARET A.Ş.

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

### FOOTNOTE 2 - GUIDELINES FOR THE PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Cont.)

#### 2.6 The Summary of Important Accounting Policies (Cont.)

##### Goodwill (Cont.)

A bargain purchase may occur, for example, in a business combination in the form of a forced sale where the seller acts under pressure. However, the recognition and measurement exceptions for certain items in TFRS 3 - Paragraphs 22-31 may also result in the recognition of a gain on a bargain purchase (or a change in the amount of the recognized gain).

Before recognizing a gain on a bargain purchase, the acquirer reassesses whether it has correctly identified the assets acquired and liabilities assumed, and also recognizes any additional assets or liabilities identified during that assessment. The acquirer then reviews the transactions used to measure the amounts of all of the following that this TFRS requires to be recognized at the acquisition date:

- (a) identifiable assets acquired and identifiable liabilities assumed;
- (b) non-controlling interests (minority interests) in the acquiree, if any;
- (c) in a business combination accomplished in stages, the acquirer's previous equity interest in the acquiree; and
- (d) The amount transferred.

The purpose of the review is to ensure that the measurements appropriately reflect all available information as of the merger date.

##### Leasing Transactions

###### Determining whether a contract contains a lease element

At the inception of a contract, the Group determines whether it is a lease or a contract with a lease element. At the inception of the contract or following its reassessment, the Group separates the payments required by such a contract as payments for leases and other matters at their fair value.

If the group determines that a reliable separation of payments is not possible for a finance lease, an asset and a liability are recognized at the fair value of the asset. The liability decreases as later payments are made and the financing costs added on the liability are recorded using the Group's alternative borrowing rate.

###### Leased assets

Assets used through leases in which all the significant risks and rewards of ownership of the asset are transferred to the Group are classified as finance leases. First of all, fixed assets obtained through finance leases are measured at the lower of the fair value of the related asset and the present value of the minimum financial lease payments. After initial recognition, it is accounted for in accordance with the accounting policies applicable to the related asset.

###### Lease payments

Minimum lease payments made under financial leasing are apportioned as financial expenses and reduction of remaining liability. Financial expenses are allocated to each period over the lease term, with a fixed period interest rate on the remaining balance of the liability.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 3 - BUSINESS COMBINATIONS**

On 11 January 2022, the Company purchased 87.633.475 shares, corresponding to 100% of the capital of Söke Değirmencilik Sanayi ve Ticaret A.Ş., 168.900.000 TL in cash and 650.000 EUR to be paid on 11 January 2023.

In the merger transactions regarding the acquisition, the financial statements of Söke Değirmencilik Sanayi ve Ticaret A.Ş. dated 31 December 2021 were used within the scope of TFRS 3 "Business Combinations" standard, since there was no significant change before the transaction date 11 January 2022.

The identifiable assets and liabilities resulting from the acquisition and the calculation of goodwill are as follows:

<b>Identifiable Assets and Liabilities</b>	<b>Fair Value</b>
Cash and cash equivalents	45.035.333
Commercial debts	103.734.344
Other receivables	10.246.709
Inventories	57.311.187
Prepaid expenses	25.265.069
Other current assets	9.474.382
Other receivables	9.482
Tangible fixed assets (*)	116.337.019
Goodwill (**)	43.251.838
Intangible assets	271.524
Right-of-use assets	1.827.172
Short-term borrowings	(129.643.499)
Trade payables	(81.065.284)
Payables within the scope of employee benefits	(746.011)
Deferred income	(5.810.074)
Short-term provisions	(8.021.650)
Other short-term liabilities	(5.062.945)
Long-term borrowings	(750.832)
Long-term provisions	(4.035.643)
Deferred tax liability	(14.750.524)
<b>Total Identifiable Net Assets</b>	<b>162.877.597</b>
<b>Share Purchased Ratio</b>	<b>100,00%</b>
<b>Fair value of payment for share acquisition (***)</b>	<b>178.373.453</b>
<b>Minus: Total Identifiable Net Assets</b>	<b>162.877.597</b>
<b>Goodwill</b>	<b>15.495.856</b>

(\*) Tangible fixed assets are the fixed assets of Söke Değirmencilik Sanayi ve Ticaret A.Ş. at the date of purchase and their fair values have been determined by an independent valuation firm authorized by the CMB.

(\*\*) Goodwill amounting to TL 43,251,838 arises from previous acquisition accounting calculations in the solo financial statements of Söke Değirmencilik Sanayi ve Ticaret A.Ş. The Company's Söke Değirmencilik Sanayi ve Ticaret A.Ş. The goodwill amounting to TL 15,495,856 arising from the merger with the Company and the amount of goodwill carried in the consolidated financial statements is TL 58,747,694 in total.

(\*\*\*) Consists of the sum of 168.900.000 TL advance payment and 650.000 EUR contingent consideration fair value at the merger date. The contingent consideration was paid on January 4, 2023 within the framework of the contract terms, and the provision for the price is followed with its fair value in the short-term provisions (Note 19) account and the changes in fair value are reflected in the consolidated financial statements in profit or loss (Note 26).

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 4 - REPORTING BY SEGMENTS**

The information grouped under reportable segments as of December 31, 2022 and December 31, 2021 are as follows:

December 31, 2022	Wheat and Flour Trade	Licensed Warehousing Services	Elimination	Total
Sales	22.848.786.440	18.688.080	(2.433.048.274)	20.434.426.246
Cost of Sales	(21.211.028.436)	(13.649.514)	2.433.048.274	(18.791.629.676)
<b>Gross Operating Profit</b>	<b>1.637.758.004</b>	<b>5.038.566</b>	<b>-</b>	<b>1.642.796.570</b>
Research and Development Expenses	(175.049)	-	-	(175.049)
General Administrative Expenses (-)	(112.514.494)	(2.011.591)	-	(114.526.085)
Marketing, Sale and Distribution Expenses (-)	(388.669.401)	-	1.000.599	(387.668.802)
Other Operating Income	1.513.178.693	2.801.968	(19.355.525)	1.496.625.136
Other Operating Expenses (-)	(1.019.112.032)	(5.914.061)	18.354.926	(1.006.671.167)
<b>Operating Profit/Loss</b>	<b>1.630.465.721</b>	<b>(85.118)</b>	<b>-</b>	<b>1.630.380.603</b>
Income from Investing Activities	80.605.459	939.525	-	81.544.984
Expenses from Investment Activities	(3.449.988)	-	-	(3.449.988)
Cancelled Impairment Earnings and Losses Determined as per TFRS 9	(3.232.945)	-	-	(3.232.945)
Shares from Profits (Losses) of Investments Valued by Equity Method	3.531.488	-	-	3.531.488
<b>Operating Profit/Loss Before Finance Expense</b>	<b>1.707.919.735</b>	<b>854.407</b>	<b>-</b>	<b>1.708.774.142</b>
Finance Income	887.992.283	16.296	(39.911.274)	848.097.305
Finance Expenses (-)	(1.767.753.016)	(12.312.249)	39.911.274	(1.740.153.991)
<b>Profit Before Tax</b>	<b>828.159.002</b>	<b>(11.441.546)</b>	<b>-</b>	<b>816.717.456</b>
Tax Expense	(107.546.190)	3.713.945	-	(103.832.245)
<b>Net Profit/Loss for the Period</b>	<b>720.612.812</b>	<b>(7.727.601)</b>	<b>-</b>	<b>712.885.211</b>

December 31, 2021	Wheat and Flour Trade	Licensed Warehousing Services	Elimination	Total
Sales	9.801.828.663	7.870.615	(500.953.723)	9.308.745.555
Cost of Sales	(9.280.437.855)	(5.824.078)	500.953.723	(8.785.308.210)
<b>Gross Operating Profit</b>	<b>521.390.808</b>	<b>2.046.537</b>	<b>-</b>	<b>523.437.345</b>
Research and Development Expenses	(20.235)	-	-	(20.235)
General Administrative Expenses (-)	(39.358.226)	(1.908.594)	-	(41.266.820)
Marketing, Sale and Distribution Expenses (-)	(142.046.654)	-	1.137.559	(140.909.095)
Other Operating Income	674.755.622	2.368.291	(2.027.708)	675.096.205
Other Operating Expenses (-)	(263.256.660)	(2.972.156)	-	(266.228.816)
<b>Operating Profit/Loss</b>	<b>751.464.655</b>	<b>(465.922)</b>	<b>(890.149)</b>	<b>750.108.584</b>
Income from Investing Activities	4.270.790	116.315	-	4.387.105
Cancelled Impairment Earnings and Losses Determined as per TFRS 9	(638.241)	-	-	(638.241)
Shares from Profits (Losses) of Investments Valued by Equity Method	1.200.919	-	-	1.200.919
<b>Operating Profit/Loss Before Finance Expense</b>	<b>756.298.123</b>	<b>(349.607)</b>	<b>(890.149)</b>	<b>755.058.367</b>
Finance Income	586.862.352	3.320.833	(8.853.573)	581.329.612
Finance Expenses (-)	(1.151.528.301)	(7.706.940)	8.853.573	(1.150.381.668)
<b>Profit Before Tax</b>	<b>191.632.174</b>	<b>(4.735.714)</b>	<b>(890.149)</b>	<b>186.006.311</b>
Tax Expense	(46.310.519)	(100.536)	-	(46.411.055)
<b>Net Profit/Loss for the Period</b>	<b>145.321.655</b>	<b>(4.836.250)</b>	<b>(890.149)</b>	<b>139.595.256</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 4 - REPORTING BY SEGMENTS (Cont.)**

<b>December 31, 2022</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing Services</b>	<b>Elimination</b>	<b>Total</b>
Total Assets	11.224.215.561	309.909.499	(1.417.989.791)	10.116.135.269
Total Liabilities	8.056.204.640	111.071.178	(866.202.247)	7.301.073.571
Parent Company Equity	3.168.010.921	198.838.321	(551.787.544)	2.815.061.698
Non-Controlling Interests	-	-	-	-

<b>December 31, 2021</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing Services</b>	<b>Elimination</b>	<b>Total</b>
Total Assets	4.156.485.368	115.494.132	(577.272.948)	3.694.706.552
Total Liabilities	3.373.490.060	39.885.112	(446.864.126)	2.966.511.046
Parent Company Equity	782.995.308	75.609.020	(130.408.822)	728.195.506
Non-Controlling Interests	-	-	-	-

<b>December 31, 2022</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing Services</b>	<b>Total</b>
Investment Expenditures	287.850.101	6.582.876	294.432.977
Depreciation Expense for the Period	49.127.882	2.928.043	52.055.925

<b>December 31, 2021</b>	<b>Wheat and Flour Trade</b>	<b>Licensed Warehousing Services</b>	<b>Total</b>
Investment Expenditures	96.443.964	6.027.199	102.471.162
Depreciation Expense for the Period	10.059.786	747.898	10.807.684

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 5 - CASH AND CASH EQUIVALENTS**

Details of the cash and cash equivalents as of December 31, 2022 and December 31, 2021 are as follows:

<b>Cash and Cash Equivalents</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Cash	73.398	81.788
Current Deposits	468.358.504	369.364.679
Term Deposits (*)	1.037.806.360	129.418.712
POS Accounts	14.778.336	358.584
Expected Credit Loss	(1.311.824)	(322.793)
	<b>1.519.704.774</b>	<b>498.900.970</b>

(\*) As of 31 December 2022, TL Term Deposit Interest Rate Range is 15% - 23.50%. The USD Term Deposit Interest Rate Range is 1%-3%. (December 31, 2021: TL Term Deposits: 21.50%-24.00% and USD Term Deposits: 0.60%-1.25%)

As of 31 December 2022 and 31 December 2021, the details of deposits in banks are as follows:

	<b>December 31, 2022</b>	<b>December 31, 2021</b>
<b>Banks</b>	<b>1.506.164.864</b>	<b>498.783.391</b>
Current Deposits	468.358.504	369.364.679
- TRY Bank	65.267.149	6.985.884
- EUR Bank	3.895.456	5.230.887
- USD Bank	397.707.823	356.751.325
- GBP Bank	34.418	43.909
- CHF Bank	293.287	352.666
- JPY Bank	-	8
- RUB Bank	1.160.371	-
Term deposit	1.037.806.360	129.418.712
- TRY Futures	747.981.861	47.728.531
- USD Futures	289.824.499	81.690.181
	<b>1.506.164.864</b>	<b>498.783.391</b>

**FOOTNOTE 6 - FINANCIAL INVESTMENTS**

Details of the financial investments as of December 31, 2022 and December 31, 2021 are as follows:

<b>Short Term Financial Investments</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Bonds	5.925.790	32.572.387
Stocks	26.109.576	-
Blocked Bank Accounts (*)	975.586.359	3.465.847
Currency Protected Deposit (**)	40.286.624	-
	<b>1.047.908.349</b>	<b>36.038.234</b>

(\*) These are blocked deposits in banks as collateral for the loans used in the 2022 period. TL 357,036,526 of blocked bank accounts consists of currency protected deposits.

(\*\*) Currency Protected TL Time Deposit Account is a deposit product that offers foreign exchange protection in case the USD exchange rate in TL increases more than the interest rate at the end of maturity. Currency protected deposit accounts are accounted for as financial assets at fair value through profit or loss.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 6 – FINANCIAL INVESTMENTS (Cont.)**

As of 31 December 2022, the nominal values and appropriate values of non-blocking currency protective deposits are as follows:

Currency	Nominal Amount (Original Currency)	Fair Value (Equivalent to TL)	Maturity
ABD Doları	2.000.000	38.352.000	21.08.2023
Euro	100.000	1.934.624	21.08.2023

**FOOTNOTE 7 – FINANCIAL BORROWINGS**

Short-term borrowings as of December 31, 2022 and December 31, 2021 are as follows:

Short-term Financial Borrowings	December 31, 2022	December 31, 2021
Short-term Borrowings	1.620.635.261	1.051.300.420
- Bank Loans	1.620.635.261	1.051.300.420
	<b>1.620.635.261</b>	<b>1.051.300.420</b>

Bank loans as of December 31, 2022 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	7%-9,5%	20.795.339	389.538.292
TRY	11,76%-36%		1.231.096.969
			<b>1.620.635.261</b>

Short-term borrowings as of December 31, 2021 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	%0,17-%5,40	37.240.807	497.187.917
TRY	%15,65-%21,00		554.112.503
			<b>1.051.300.420</b>

Short-term portions of long-term borrowings as of December 31, 2022 and December 31, 2021 are as follows:

Short-term Portions of Long-term Borrowings	December 31, 2022	December 31, 2021
Principal Instalments of Long-term Loans	766.336.251	256.426.341
Borrowings from Rental Transactions	6.233.605	10.132.618
	<b>772.569.856</b>	<b>266.558.959</b>

Short-term portions of long-term borrowings as of December 31, 2022 are as follows:

Currency	Interest Rate Range	Amount in Foreign Currency	Amount in TRY
USD	7,2%-9%	7.758.579	145.333.711
TRY	3%-%26		621.002.540
			<b>766.336.251</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 7 – FINANCIAL BORROWING (Cont.)**

Short-term portions of long-term borrowings as of December 31, 2021 are as follows:

<b>Currency</b>	<b>Interest Rate Range</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>
USD	%4,32-%5,63	3.946.769	52.701.206
TRY	%7,52-%24		203.725.135
			<b>256.426.341</b>

Payables related to short-term leases as of December 31, 2022 are as follows:

<b>Currency</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>
USD	123.117	2.306.228
TRY		3.927.377
		<b>6.233.605</b>

Payables related to short-term leases as of December 31, 2021 are as follows:

<b>Currency</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>
USD	639.214	8.535.421
TRY		1.597.197
		<b>10.132.618</b>

Long-term borrowings as of December 31, 2022 and December 31, 2021 are as follows:

<b>Long-term Borrowings</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Long-term Bank Loans	837.236.247	278.166.522
Borrowings from Rental Transactions	2.757.969	4.084.604
	<b>839.994.216</b>	<b>282.251.126</b>

Long-term borrowings as of December 31, 2022 are as follows:

<b>Currency</b>	<b>Interest Rate Range</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>
USD	9,01%	23.239.967	435.331.058
TRY	3,48%-26%		401.905.189
			<b>837.236.247</b>

Long-term borrowings as of December 31, 2021 are as follows:

<b>Currency</b>	<b>Interest Rate Range</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>
USD	5,63%	9.920.474	132.468.092
TRY	%7,52-24%		145.698.430
			<b>278.166.522</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 7 – FINANCIAL BORROWING (Cont.)**

Payables related to long-term leases as of December 31, 2022 are as follows:

<b>Currency</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>
TRY		2.757.969
		<b>2.757.969</b>

Payables related to long-term leases as of December 31, 2021 are as follows

<b>Currency</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>
USD	123.117	1.643.983
TRY		2.440.621
		<b>4.084.604</b>

The details of the loans used as of December 31, 2022 are as follows;

<b>Currency</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>	<b>Loan Type</b>
USD	5.160.906	96.674.092	Spot Loan
USD	36.882.979	690.891.967	Usd Installment
USD	9.750.000	182.637.000	Rotary
TRY		364.502.486	Rotary
TRY		1.089.851.777	Installment Loan
TRY		679.400.000	Spot Loan
TRY		120.250.437	Participation Banks
	<b>51.793.885</b>	<b>3.224.207.759</b>	

The details of the loans used as of December 31, 2021 are as follows;

<b>Currency</b>	<b>Amount in Foreign Currency</b>	<b>Amount in TRY</b>	<b>Loan Type</b>
USD	19.800.000	264.389.400	CBT Rediscount Loan
USD	13.867.243	185.169.298	Usd Installment
USD	17.440.807	232.798.517	Rotary
TRY		400.429.114	TRY Installment Loan
TRY		419.830.876	Spot Loan
TRY		83.276.078	Participation Banks
	<b>51.108.050</b>	<b>1.585.893.283</b>	



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 8 – TRADE RECEIVABLES AND PAYABLES**

Short-term trade receivables as of December 31, 2022 and December 31, 2021 are as follows:

<b>Short Term Trade Receivables</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Trade Receivables From Related Parties	101.569.916	375.857
Trade Receivables From Unrelated Parties (*)	2.726.957.264	1.064.359.274
Notes Receivable from Related Parties	-	5.478.936
Notes Receivable from Unrelated Parties	152.125.037	91.364.305
Deferred Interest Income (-)	(33.813.707)	(8.516.553)
Doubtful Trade Receivables	13.598.824	6.815.828
Provision for Doubtful Trade Receivables (-)	(13.598.824)	(6.815.828)
	<b>2.946.838.510</b>	<b>1.153.061.819</b>

(\*) The amount of 127,569,070 TL included in trade receivables; Within the scope of the contract signed with the Turkish Grain Board ("TMO"), it has been accounted for for the deliveries of bread wheat allocations to be received from TMO in return for the wheat flour sales made at the price committed to the market during the October, November, and December 2022 period.

The Group has the option to buy wheat from TMO below the market price in comparison to the sale, in return for selling flour below the market price to the customers determined within the scope of its commitment to TMO. The Group management has determined the benefit to be obtained as government incentives as the remaining amount after deducting the revenue amount determined according to the sales price alone from the total contract price, within the scope of the accounting policy created by making analogy to paragraph 10A of TAS 20 Standard for Accounting for Government Incentives and Disclosure of Government Aids. Since the benefit obtained within the scope of the commitment given to TMO does not exceed the stand-alone selling price, it is considered as revenue.

As of 31 December 2022 and 31 December 2021, the movements of doubtful trade receivables during the period are as follows:

<b>Doubtful Trade Receivables</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Doubtful Trade Receivables at the Beginning of the Period	6.815.828	7.521.114
Provision During the Period	8.882.888	3.642.617
Affiliate Login	1.859.964	-
Canceled Provision (-)	(3.959.856)	(4.347.903)
	<b>13.598.824</b>	<b>6.815.828</b>

Long-term trade receivables as of December 31, 2022 and December 31, 2021 are as follows:

<b>Long Term Trade Receivables</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Trade Receivables From Related Parties	-	-
Trade Receivables From Unrelated Parties (*)	10.197.097	10.197.097
	<b>10.197.097</b>	<b>10.197.097</b>

(\*) See Footnote 19.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 8 – TRADE RECEIVABLES AND PAYABLES (Cont.)**

Short-term trade payables as of December 31, 2022 and December 31, 2021 are as follows:

<b>Short Term Trade Payables</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Trade Payables to Related Parties	4.117.214	5.822.384
Trade Payables to Unrelated Parties (*)	3.091.757.326	1.137.258.341
Notes Payable to Unrelated Parties	4.500.000	5.519.018
Deferred Interest Expense (-)	(17.019.726)	(9.309.790)
	<b>3.083.354.814</b>	<b>1.139.289.953</b>

(\*) As of 31 December 2022, TL 2.110.489.228 of trade payables to non-related parties consists of letter of credit payables. (31 December 2021: 1.025.497.706 TL)

**FOOTNOTE 9 – OTHER RECEIVABLES AND PAYABLES**

Other short-term receivables as of December 31, 2022 and December 31, 2021 are as follows:

<b>Other Short-term Receivables</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Deposits and Guarantees Given	146.245	279.437
Other Receivables from Related Parties	-	600
Receivables from Public Bodies	57.540.775	4.556.953
Receivables from Employees	-	25.300
	<b>57.687.020</b>	<b>4.862.290</b>

Other long-term receivables from unrelated parties as of December 31, 2022 and December 31, 2021 are as follows:

<b>Other Long-term Receivables</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Deposits and Guarantees Given	832.953	543.541
	<b>832.953</b>	<b>543.541</b>

Other short-term payables as of December 31, 2022 and December 31, 2021 are as follows:

<b>Other Short-term Payables</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Other Payables to Unrelated Parties	279.174	127.817
Other Payables to Related Parties	205.312.078	8.707.586
	<b>205.591.252</b>	<b>8.835.403</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 10 – DERIVATIVE INSTRUMENTS**

Derivative financial assets as of December 31, 2022 and December 31, 2021 are as follows:

<b>Derivative Financial Assets</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Derivatives Market Collaterals	15.440.035	138.625.143
Derivative Financial Instruments	128.635.606	86.749.627
	<b>144.075.641</b>	<b>225.374.770</b>

Derivative financial liabilities as of December 31, 2022 and December 31, 2021 are as follows:

<b>Derivative Financial Liabilities</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Derivative Financial Instruments	65.554.675	55.543
	<b>65.554.675</b>	<b>55.543</b>

(\*) The guarantees given for trading in the futures market are classified as futures market guarantees, the fair values of forward contracts and option contracts are classified as derivative financial instruments. Profits or losses resulting from transactions made during the period; Derivative financial instrument income and expenses are reported under finance income and expenses in the profit or loss statement, and the fair value differences of open positions as of the reporting date are reported under finance income and expenses.

**Fair Value of Financial Instruments**

Based on the source of valuation inputs of each financial instrument class, the Group categorizes the financial instruments recognized at fair value according to the three-level hierarchy.

Level 1: Valuation techniques using quoted prices in active markets for identical assets or liabilities that the Group has the ability to access at the measurement date;

Level 2: Other valuation techniques involving inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly;

Level 3: Valuation techniques using unobservable inputs for the assets or liability.

<b>December 31, 2022</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Forward Exchange Contracts (for Trade Purposes)	-	78.520.966	-
	-	<b>78.520.966</b>	-
<b>December 31, 2021</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Forward Exchange Contracts (for Trade Purposes)	-	225.319.227	-
	-	<b>225.319.227</b>	-

Forward exchange transactions (Level 2) are valued using foreign exchange rates on the date of the balance sheet and discounting the fair value of the forward exchange contract to the present day.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 11 – INVENTORIES**

Inventories as of December 31, 2022 and December 31, 2021 are as follows:

<b>Inventories</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Raw Materials and Supplies	500.041.115	190.521.591
Finished Goods	196.849.395	17.003.486
Merchandise	387.639.931	605.287.606
Other Inventories	8.572.823	1.313.014
Provision for Inventory Impairment (-)	(123.378)	(146.486)
Semi-Finished Goods	190.297.147	46.146.728
	<b>1.283.277.033</b>	<b>860.125.939</b>

There is no lien, claim or pledge on the inventories, which are insured.

**FOOTNOTE 12 - PREPAID EXPENSES AND DEFERRED INCOME**

Short-term prepaid expenses as of December 31, 2022 and December 31, 2021 are as follows:

<b>Short-term Prepaid Expenses</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Advances Given for Purchase Orders with Related Parties	9.469.792	6.898.543
Advances Given for Purchase Orders Placed with Unrelated Parties	179.842.753	178.351.308
Insurance and Other Pre-paid Expenses	24.895.856	1.967.326
	<b>214.208.401</b>	<b>187.217.176</b>

Long-term prepaid expenses as of December 31, 2022 and December 31, 2021 are as follows:

<b>Long-term Prepaid Expenses</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Insurance Expenses	20.460.393	4.985.613
Advances Given for Purchase Orders with Unrelated Parties	3.042.013	3.042.014
	<b>23.502.406</b>	<b>8.027.627</b>

Short-term deferred income as of December 31, 2022 and December 31, 2021 is as follows:

<b>Short-term Deferred Income</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Advances Received from Related Parties	-	428.212
Advances Received from Unrelated Parties	100.421.758	73.797.080
	<b>100.421.758</b>	<b>74.225.292</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 13 – INVESTMENTS VALUED BY EQUITY METHOD**

Investments valued by equity method as of December 31, 2022 and December 31, 2021 are as follows:

Name of Affiliate	%	December 31, 2022	%	December 31, 2021
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	17	7.808.666	17	5.316.148

Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	January 1 - December 31, 2022	January 1 - December 31, 2021
<b>As of January, 1</b>	5.316.148	4.936.299
Shares of Profits/Losses	3.531.488	1.200.919
Shares of Other Comprehensive Income / Expenses	(104.897)	(38.934)
Accrued Dividend Income	(934.073)	(782.136)
<b>End of the Period</b>	<b>7.808.666</b>	<b>5.316.148</b>

The summary financial statements of the investment accounted for using the equity method are as follows:

Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	December 31, 2022	December 31, 2021
Current Assets	23.873.307	9.238.620
Fixed Assets	14.809.392	9.519.273
<b>Total Assets</b>	<b>38.682.699</b>	<b>18.757.893</b>
Short Term Liabilities	8.665.945	3.966.827
Long Term Liabilities	4.040.326	3.476.507
Equities	25.976.428	11.314.559
<b>Total Resources</b>	<b>38.682.699</b>	<b>18.757.893</b>

	January 1 - December 31, 2022	January 1 - December 31, 2021
Sales Revenues	47.491.268	13.436.279
Net Profit/(Loss) for the Period	20.773.457	7.064.232

As of 31 December 2022 and 31 December 2021, the details of the shares in the profits / losses of the investments valued by the equity method are as follows:

	January 1 - December 31, 2022	January 1 - December 31, 2021
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşleticisi A.Ş.	3.531.488	1.200.919
	<b>3.531.488</b>	<b>1.200.919</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 14 – INVESTMENT PROPERTIES**

Investment properties as of December 31, 2022 and December 31, 2021 are as follows:

<b>Description</b>	<b>January 1, 2022</b>	<b>Acquisitions</b>	<b>Re-Appraisal</b>	<b>Transfers</b>	<b>December 31, 2022</b>
Plot of Land	9.297.000	-	(9.297.000)	-	-
Building	6.995.000	-	(6.719.000)	692.000	968.000
<b>Total Cost</b>	<b>16.292.000</b>	<b>-</b>	<b>(16.016.000)</b>	<b>692.000</b>	<b>968.000</b>

<b>Description</b>	<b>January 1, 2021</b>	<b>Acquisitions</b>	<b>Re-Appraisal</b>	<b>Transfers</b>	<b>December 31, 2021</b>
Plot of Land	8.283.231	-	1.013.769	-	9.297.000
Building	4.580.454	-	2.414.546	-	6.995.000
<b>Total Cost</b>	<b>12.863.685</b>	<b>-</b>	<b>3.428.315</b>	<b>-</b>	<b>16.292.000</b>

Investment properties are reported at their fair values. The fair value differences of investment properties are reported in the income/expenses account from investment activities.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 15 – ASSETS RELATED TO CURRENT PERIOD TAX**

Assets relating to current tax as of December 31, 2022 and December 31, 2021 are as follows:

<b>Assets Related to Current Period Tax</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Prepaid Taxes and Funds	87.611.727	8.278.620
	<b>87.611.727</b>	<b>8.278.620</b>

**FOOTNOTE 16 – RIGHT-OF-USE ASSETS**

Right-of-use assets as of December 31, 2022 and December 31, 2021 are as follows:

<b>Description</b>	<b>January 1, 2022</b>	<b>Entries</b>	<b>Outputs</b>	<b>Transfers</b>	<b>Subsidiary Acquisition</b>	<b>December 31, 2022</b>
Buildings	1.505.990	747.474	(54.369)	-	-	2.199.095
Vehicles	4.179.794	3.719.888	(496.777)	-	3.978.355	11.381.260
<b>Total</b>	<b>5.685.784</b>	<b>4.467.362</b>	<b>(551.146)</b>	<b>-</b>	<b>3.978.355</b>	<b>13.580.355</b>

Buildings	(693.800)	(643.666)	54.368	-	-	(1.283.098)
Vehicles	(1.334.283)	(3.322.798)	496.777	-	(2.151.183)	(6.311.487)
<b>Accumulated Depreciation</b>	<b>(2.028.083)</b>	<b>(3.966.464)</b>	<b>551.145</b>	<b>-</b>	<b>(2.151.183)</b>	<b>(7.594.585)</b>
<b>Net Book Value</b>	<b>3.657.701</b>					<b>5.985.770</b>

<b>Description</b>	<b>January 1, 2021</b>	<b>Entries</b>	<b>Outputs</b>	<b>Transfers</b>	<b>Subsidiary Acquisition</b>	<b>December 31, 2021</b>
Buildings	2.008.867	-	(502.877)	-	-	1.505.990
Vehicles	1.617.902	2.576.373	(14.481)	-	-	4.179.794
<b>Total</b>	<b>3.626.769</b>	<b>2.576.373</b>	<b>(517.358)</b>	<b>-</b>	<b>-</b>	<b>5.685.784</b>

Buildings	(388.331)	(415.407)	109.938	-	-	(693.800)
Vehicles	(842.859)	(500.112)	8.688	-	-	(1.334.283)
<b>Accumulated Depreciation</b>	<b>(1.231.190)</b>	<b>(915.519)</b>	<b>118.626</b>	<b>-</b>	<b>-</b>	<b>(2.028.083)</b>
<b>Net Book Value</b>	<b>2.395.579</b>					<b>3.657.701</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 17 – TANGIBLE ASSETS**

As of 31 December 2022, the details of tangible assets are as follows:

Description	January 1, 2022	Acquisitions	Disposals	Transfers	Re-Appraisal (*)	Subsidiary Acquisition	December 31, 2022
Lands and Plots	102.458.001	17.423.615	-	-	415.724.797	20.748.000	556.354.413
Buildings	117.732.197	18.475.497	-	2.951.129	338.398.430	25.143.495	502.700.748
Underground and Ground Plants	4.805.499	3.751.606	-	173.365	15.995.820	2.711.941	27.438.231
Facilities, Machinery and Equipment	312.717.633	77.875.406	(2.953.566)	3.061.532	570.318.996	62.101.001	1.023.121.002
Vehicles	15.893.662	79.052.577	(9.024.834)	-	84.540.599	3.604.998	174.067.002
Fixtures	10.134.206	4.894.737	(170.870)	39.259	-	2.572.519	17.469.851
Special Costs	5.699.300	192.199	(9.856.137)	(340.641)	-	10.196.778	5.891.499
Ongoing Investments	37.323.818	58.462.247	(192.501)	(5.884.644)	-	62.629	89.771.549
Advances Given(*)	-	31.330.007	-	-	-	-	31.330.007
<b>Total Cost</b>	<b>606.764.316</b>	<b>291.457.891</b>	<b>(22.197.908)</b>	<b>-</b>	<b>1.424.978.642</b>	<b>127.141.361</b>	<b>2.428.144.302</b>
Accumulated Depreciation	January 1, 2022	Acquisitions	Disposals	Transfers	Re-Appraisal (*)	Subsidiary Acquisition	December 31, 2022
Lands and Plots	-	-	-	-	-	-	-
Buildings	(637.277)	(4.668.441)	-	-	5.305.718	-	-
Underground and Ground Plants	(214.625)	(760.816)	-	-	656.827	-	(318.614)
Facilities, Machinery and Equipment	(3.374.906)	(30.638.377)	136.529	-	33.876.754	-	-
Vehicles	(6.971.886)	(8.460.296)	1.077.310	-	14.354.872	-	-
Fixtures	(2.494.098)	(2.458.047)	122.692	-	-	(1.575.107)	(6.404.560)
Special Costs	(186.851)	(595.895)	9.229.235	-	-	(9.229.235)	(782.746)
<b>Total</b>	<b>(13.879.643)</b>	<b>(47.581.872)</b>	<b>10.565.766</b>	<b>-</b>	<b>54.194.171</b>	<b>(10.804.342)</b>	<b>(7.505.920)</b>
<b>Tangible Assets (Net)</b>	<b>592.884.673</b>						<b>2.420.638.382</b>

(\*) As of 31 December 2022, TL 30,802,500 consists of the invoiced amount for the pre-allocation of the land within the scope of the paid parcel allocation agreement signed by the Group with Samsun Gıda İhtisas Organized Industrial Zone.

As of 31 December 2022, there are bank mortgages on fixed assets amounting to 50.000.000-USD and 10.175.000 TL in total. (31 December 2021 64.800.000 USD and 8.475.000 TL)

The Group has shown the tangible fixed assets, for which the revaluation model has been adopted, with the revalued amounts calculated over their fair values. As of 31 December 2022 and 31 December 2021, the difference between the fair value of the said assets and their net book value; It is added to tangible fixed assets in assets and to "Tangible Fixed Assets Revaluation Increases (Decreases)" in liabilities.



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 17 – TANGIBLE ASSETS (Cont.)**

As of 31 December 2021, the details of tangible assets are as follows:

<b>Description</b>	<b>January 1, 2021</b>	<b>Acquisitions</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Re-Appraisal</b>	<b>December 31, 2021</b>
Lands and Plots	23.141.629	30.984.949	(536.254)		48.867.677	102.458.001
Buildings	84.302.093	6.043.172	-		27.386.932	117.732.197
Underground and Ground Plants	4.530.713	274.786	-		-	4.805.499
Facilities, Machinery and Equipment	182.909.160	15.144.395	(1.690.650)		116.354.728	312.717.633
Vehicles	14.363.043	2.250.356	(695.957)	(23.780)	-	15.893.662
Fixtures	4.759.051	5.398.506	(47.131)	23.780	-	10.134.206
Special Costs	82.081	5.617.219	-		-	5.699.300
Ongoing Investments	3.259.198	34.064.620	-		-	37.323.818
<b>Total Cost</b>	<b>317.346.968</b>	<b>99.778.003</b>	<b>(2.969.992)</b>	<b>-</b>	<b>192.609.337</b>	<b>606.764.316</b>
<b>Accumulated Depreciation</b>	<b>January 1, 2021</b>	<b>Acquisitions</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Re-Appraisal</b>	<b>December 31, 2021</b>
Lands and Plots	-	-	-	-	-	-
Buildings	(6.035.873)	(637.277)	6.035.873	-	-	(637.277)
Underground and Ground Plants	(113.337)	(101.288)	-	-	-	(214.625)
Facilities, Machinery and Equipment	(21.018.077)	(3.374.660)	21.017.831	-	-	(3.374.906)
Vehicles	(3.410.955)	(3.779.934)	219.003	-	-	(6.971.886)
Fixtures	(1.158.416)	(1.363.136)	27.454	-	-	(2.494.098)
Special Costs	(12.579)	(174.272)	-	-	-	(186.851)
<b>Total</b>	<b>(31.749.237)</b>	<b>(9.430.567)</b>	<b>27.300.161</b>	<b>-</b>	<b>-</b>	<b>(13.879.643)</b>
<b>Tangible Assets (Net)</b>	<b>285.597.731</b>					<b>592.884.673</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 18 – INTANGIBLE ASSETS**

Intangible assets as of December 31, 2022 and December 31, 2021 are as follows:

<b>Description</b>	<b>January 1, 2022</b>	<b>Acquisitions</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Subsidiary Acquisition</b>	<b>December 31, 2022</b>
Rights (Computer Software)	866.401	2.191.475	-	-	1.250.738	4.308.614
Trademark Rights	1.639.022	310.804	-	-	-	1.949.826
Ongoing Investments	1.842.130	472.807	-	-	-	2.314.937
<b>Total Cost</b>	<b>4.347.553</b>	<b>2.975.086</b>	<b>-</b>	<b>-</b>	<b>1.250.738</b>	<b>8.573.377</b>

  

<b>Accumulated Depreciation</b>	<b>January 1, 2022</b>	<b>Expenses for the Period</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Subsidiary Acquisition</b>	<b>December 31, 2022</b>
Rights (Computer Software)	(469.453)	(248.395)	-	-	(979.215)	(1.697.063)
Trademark Rights	(290.290)	(259.191)	-	-	-	(549.481)
<b>Total</b>	<b>(759.743)</b>	<b>(507.586)</b>	<b>-</b>	<b>-</b>	<b>(979.215)</b>	<b>(2.246.544)</b>
<b>Intangible Assets (Net)</b>	<b>3.587.810</b>					<b>6.326.833</b>

  

<b>Description</b>	<b>January 1, 2021</b>	<b>Acquisitions</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Subsidiary Acquisition</b>	<b>December 31, 2021</b>
Rights (Computer Software)	545.121	321.280	-	-	-	866.401
Trademark Rights	324.724	1.314.298	-	-	-	1.639.022
Ongoing Investments	784.547	1.057.583	-	-	-	1.842.130
<b>Total Cost</b>	<b>1.654.392</b>	<b>2.693.161</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4.347.553</b>

  

<b>Accumulated Depreciation</b>	<b>January 1, 2021</b>	<b>Expenses for the Period</b>	<b>Disposals</b>	<b>Transfers</b>	<b>Subsidiary Acquisition</b>	<b>December 31, 2021</b>
Rights (Computer Software)	(147.661)	(321.792)	-	-	-	(469.453)
Trademark Rights	(150.480)	(139.810)	-	-	-	(290.290)
<b>Total</b>	<b>(298.141)</b>	<b>(461.602)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(759.743)</b>
<b>Intangible Assets (Net)</b>	<b>1.356.251</b>					<b>3.587.810</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 19 - PROVISIONS, CONTINGENT ASSETS AND LIABILITIES**

Short-term provisions as of December 31, 2022 and December 31, 2021 are as follows:

<b>Short-term Provisions</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Other Provisions	1.442.647	425.000
Contingent Value Reserve (Note 3)	12.858.170	-
	<b>14.300.817</b>	<b>425.000</b>

As of 31 December 2022 and 31 December 2021 of the Group; Samsun Feed Industry and Trade Inc. ("Samsun Yem"), Yemsel Tavukçuluk Animal Husbandry Yem Ham Maddeleri Sanayi ve Ticaret A.Ş. ("Yemsel") and Çakıroğlu Gıda Tarım Ürünleri Livestock and Feed Tavukçuluk Nakliyat Ticaret ve Sanayi A.Ş. ("Çakıroğlu") details of their receivables are as follows:

<b>Company Title (*)</b>	<b>Trade Receivables</b>	<b>Advances Given for Purchase Orders</b>	<b>Total</b>	<b>Liens Received</b>
Samsun Yem	1.232.128		1.232.128	700.000
Yemsel	1.293.727	3.042.014	4.335.741	6.000.000
Çakıroğlu	7.671.242		7.671.242	10.000.000
	<b>10.197.097</b>	<b>3.042.014</b>	<b>13.239.111</b>	<b>16.700.000</b>

(\*) It will be collectively referred to as Çakıroğlu Group.

Samsun Yem, Yemsel and Çakıroğlu, T.C. He applied to Samsun Commercial Court of First Instance with a request for postponement of bankruptcy. The Group has established mortgages on the real estates of Samsun Yem, Yemsel and Çakıroğlu for its receivables detailed above. The mortgage established by the Group allows all receivables to be claimed on any mortgaged real estate belonging to Çakıroğlu Group. Samsun Yem and Çakıroğlu are in the 1st place in mortgages. It ranks 2nd in the mortgage placed on Yemsel's real estate. Akbank T.A.Ş. ranks 1st in Yemsel's real estate mortgage. is located. The total mortgage amount of Akbank T.A.Ş. is 6,000,000 TL.

A notification was sent to Çakıroğlu Group regarding the payment of its debts. On 8 January 2016, a valuation was requested for the real estates. On December 29, 2016, an exploration was made with the court committee for valuation. On 18 January 2017, the experts submitted their reports to the court. A total value of 10,858,440,75 TL has been appraised for the mortgaged real estate belonging to Çakıroğlu. A total value of 11,527,728,25 TL has been appraised for the mortgaged real estate belonging to Yemsel. For the mortgaged real estate belonging to Samsun Yem, a total value of 263,249,19 TL was appraised.

Samsun Feed Industry and Trade Inc. The decision to postpone the bankruptcy was rejected by the Samsun Commercial Court of First Instance on September 30, 2020. The Group has requested a revaluation for the real estates. Samsun Commercial Court of First Instance issued a bankruptcy decision for Çakıroğlu and Yemsel on 30 September 2020.

As of the end of the year, the Group had the Varlık Real Estate Appraisal and Consultancy Company issue real estate valuation reports for the 1st rank mortgaged real estates on the Çakıroğlu and Samsun Yem real estates, and the total value of the two real estates was determined as 13,364,000 TL. Since the fair values of the mortgages and real estates in the valuation reports are sufficient to cover the entire receivable, no provision has been made.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 19 - PROVISIONS, CONTINGENT ASSETS AND LIABILITIES (Cont.)**

Assurance, pleadings and lien as of December 31, 2022 and December 31, 2021 are as follows:

<b>December 31, 2022</b>	<b>TRY Amount</b>	<b>USD</b>	<b>EUR</b>	<b>TRY</b>
Total amount of assurance, pleadings and lien given by its own legal entity and other companies within the scope of consolidation				
-Assurance	457.188.465	5.980.600	2.000.000	305.491.612
-Lien	945.090.000	50.000.000	-	10.175.000
-Pleadings	-	-	-	-
<b>Total</b>	<b>1.402.278.465</b>	<b>55.980.600</b>	<b>2.000.000</b>	<b>315.666.612</b>
<b>December 31, 2021</b>	<b>TRY Amount</b>	<b>USD</b>	<b>EUR</b>	<b>TRY</b>
Total amount of assurance, pleadings and lien given by its own legal entity and other companies within the scope of consolidation				
-Assurance	170.649.068	5.536.713	2.000.000	66.676.827
-Lien	872.194.200	64.800.000	-	8.475.000
-Pleadings	-	-	-	-
<b>Total</b>	<b>1.042.843.268</b>	<b>70.336.713</b>	<b>2.000.000</b>	<b>75.151.827</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 20 – PROVISIONS RELATED TO EMPLOYEE BENEFITS**

Within the framework of the existing laws in Türkiye, the Group has completed a one-year service period and has been terminated without any valid reason, has been called up for military service, has passed away, has completed 25 years of service for men and 20 years for women, and has reached retirement age (for women). 58, 60 for men) must be paid severance pay. Due to the amendment of the legislation as of 8 September 1999, there are certain transitional obligations related to the length of service due to retirement.

As of 31 December 2022, these payments are calculated based on the rate on the day of retirement or termination per year worked, up to a maximum of TL 19,982.83 (December 31, 2021: TL 8,284,51) over the 30-day salary. The provision for severance pay is calculated on a current basis and reflected in the financial statements. Provision is calculated by estimating the present value of the Group's future probable obligation arising from the retirement of its employees. The calculation is made according to the severance pay ceiling announced by the Government.

Severance pay liability is calculated by estimating the present value of the future probable obligation of the Group arising from the retirement of its employees. TFRS requires the Group's liabilities to be calculated using actuarial valuation methods within the scope of defined benefit plans. Accordingly, the actuarial assumptions used in the calculation of total liabilities are given below.

The basic assumption is that the maximum liability for each year of service will increase in line with inflation. Thus, the discount rate applied represents the expected real interest rate after adjusting for the effects of future inflation. As a result, the liabilities in the accompanying consolidated financial statements as of 31 December 2022 are calculated by estimating the present value of the future probable obligation arising from the retirement of the employees. The provision for 31 December 2022 is calculated at a discount rate of approximately 2.54 percent, assuming an annual inflation rate of 18.00 percent and an interest rate of 21.00 percent. (The provision at 31 December 2021 is calculated at a discount rate of approximately 5.68 percent, assuming an annual inflation rate of 14.50 percent and an interest rate of 21.00 percent.)

Provision for severance pay as of December 31, 2022 and December 31, 2021 is as follows:

	<b>December 31, 2022</b>	<b>December 31, 2021</b>
<b>Balance on January 1</b>	3.657.593	2.564.363
Current Service Cost	4.681.552	685.617
Cost of Interest	5.146.205	768.094
Subsidiary Acquisition	4.035.643	-
Payments within the Period	(2.825.196)	(1.052.118)
Actuarial Difference	9.809.939	691.637
<b>End of Period Balance</b>	<b>24.505.736</b>	<b>3.657.593</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 20 – PROVISIONS RELATED TO EMPLOYEE BENEFITS (Cont.)**

Short-term provisions related to employee benefits as of December 31, 2022 and December 31, 2021 are as follows:

<b>Short-term Employee Benefits</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Provisions for Accumulated Leave	3.032.935	157.474
	<b>3.032.935</b>	<b>157.474</b>

Payables related to employee benefits as of December 31, 2022 and December 31, 2021 are as follows:

<b>Payables Related to Employee Benefits</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Social Security Premiums Payable	3.718.099	814.020
Payables to Personnel	7.440.650	1.887.234
	<b>11.158.749</b>	<b>2.701.254</b>

**FOOTNOTE 21 – OTHER ASSETS AND LIABILITIES**

Other current assets as of December 31, 2022 and December 31, 2021 are as follows:

<b>Other Current Assets</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Deductible VAT	32.334.907	28.821.521
Advance Payments to Personnel	3.468	15.048
Business Advance Payments	1.677	1.891
Other VAT	10.869	31.286
	<b>32.350.921</b>	<b>28.869.746</b>

Other short-term liabilities as of December 31, 2022 and December 31, 2021 are as follows:

<b>Other Short-term Liabilities</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Taxes and Funds Payable	78.605.280	20.434.155
Accrued Expenses	16.912.638	223.635
Other Obligations Payable	30.000	-
Overdue, Deferred or Installed Taxes and Other Liabilities	738.192	1.432.770
	<b>96.286.110</b>	<b>22.090.560</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 22 – EQUITIES****Capital and Reserves**

As of 31 December 2022, the issued capital of the Company is 190.970.000 TL. (One hundred ninety-one million nine hundred and seventy thousand Turkish Liras) This capital is divided into 190.970.000 shares, each of which has a nominal value of 1 TL, 22.035.000 Group A, 14.690.000 Group B and 154.245.000 Group C.

As a result of the share transfer made with the decision of the Board of Directors dated 6 May 2022, the capital structure of the Company as of 31 December 2022 is as follows:

Shareholders	Number of Shares	Group	Percentage (%)	Amount
Nevin Ulusoy	9.548.501	A	5,00	9.548.501
	2.938.000	B	1,54	2.938.000
	23.589.237	C	12,35	23.589.237
	<b>36.075.738</b>		<b>18,89</b>	<b>36.075.738</b>
Onur Erhan Ulusoy	1.469.000	A	0,77	1.469.000
	3.407.000	B	1,78	3.407.000
	13.024.001	C	6,82	13.024.001
	<b>17.900.001</b>		<b>9,37</b>	<b>17.900.001</b>
Eren Günhan Ulusoy	11.017.499	A	5,77	11.017.499
	8.345.000	B	4,37	8.345.000
	52.380.358	C	27,43	52.380.358
	<b>71.742.857</b>		<b>37,57</b>	<b>71.742.857</b>
Mithat Denizcigil	215.518	C	0,11	215.518
	<b>215.518</b>		<b>0,11</b>	<b>215.518</b>
Kâmil Adem	60.887	C	0,03	60.887
	<b>60.887</b>		<b>0,03</b>	<b>60.887</b>
Publicly-held	<b>64.975.000</b>	C	<b>34,02</b>	<b>64.975.000</b>
<b>Total</b>	<b>190.970.000</b>		<b>100,00</b>	<b>190.970.000</b>

With the decision of the board of directors dated 5 January 2021, the company increased its paid-in capital, which was 84.500.000,00 TL as of 31 December 2020, to 190.970.000,00 TL with an increase of 126%, all of which were bonus issues from internal resources.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 22 – EQUITIES (Cont.)**

The Company's capital structure as of December 31, 2021 is as follows:

Shareholders	Number of Shares	Group	Percentage (%)	Amount
Fahrettin Ulusoy	10.283.000	A	5,38	10.283.000
	4.407.000	B	2,31	4.407.000
	-	C	-	-
	<b>14.690.000</b>		<b>7,69</b>	<b>14.690.000</b>
Nevin Ulusoy	1.469.000	A	0,77	1.469.000
	2.938.000	B	1,54	2.938.000
	27.589.237	C	14,45	27.589.237
	<b>31.996.237</b>		<b>16,76</b>	<b>31.996.237</b>
Onur Erhan Ulusoy	1.469.000	A	0,77	1.469.000
	3.407.000	B	1,78	3.407.000
	13.024.001	C	6,82	13.024.001
	<b>17.900.001</b>		<b>9,37</b>	<b>17.900.001</b>
Eren Günhan Ulusoy	8.814.000	A	4,62	8.814.000
	3.938.000	B	2,06	3.938.000
	48.380.357	C	25,33	48.380.357
	<b>61.132.357</b>		<b>32,01</b>	<b>61.132.357</b>
Mithat Denizcigil	215.518	C	0,11	215.518
	<b>215.518</b>		<b>0,11</b>	<b>215.518</b>
Kâmil Adem	60.887	C	0,03	60.887
	<b>60.887</b>		<b>0,03</b>	<b>60.887</b>
Publicly-held	64.975.000	C	34,02	64.975.000
<b>Total</b>	<b>190.970.000</b>		<b>100,00</b>	<b>190.970.000</b>

According to the Turkish Commercial Code, legal reserves are divided into two as first and second legal reserves. According to the Turkish Commercial Code, primary legal reserves are set aside as 5% of the legal net profit until 20% of the paid-in capital of the Company is reached.

Publicly traded companies make their dividend distributions in accordance with the CMB's Dividend Communiqué No. II-19.1.

Partnerships distribute their profits within the framework of the profit distribution policies to be determined by their general assemblies and in accordance with the provisions of the relevant legislation. Within the scope of the said communiqué, a minimum distribution rate has not been determined. Companies distribute dividends as determined in their articles of association or dividend policy. In addition, dividends can be paid in installments of equal or different amounts, and dividend advances can be distributed in cash over the profit included in the financial statements.

Unless the reserves required to be set aside in accordance with the Turkish Commercial Code and the dividend determined for the shareholders in the articles of association or the profit distribution policy are reserved; It cannot be decided to allocate other reserves, to transfer profits to the next year, and to distribute dividends to shareholders, members of the board of directors, partnership employees and non-shareholders.



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 22 – EQUITIES (Cont.)**

Equity items as of December 31, 2022 and December 31, 2021 are as follows:

<b>EQUITIES</b>	<b>1 January- 31 December 2022</b>	<b>1 January- 31 December 2021</b>
Paid-in capital	190.970.000	190.970.000
Repurchased Shares	(64.567.763)	(26.765.386)
Premiums on Shares (Discounts)	15.269.029	15.269.029
Other Accumulated Comprehensive Income (Expenses) Not to be Reclassified to Profit or Loss	1.574.556.913	251.661.140
- <i>Property, Plant and Equipment Revaluation Increases / (Decreases)</i>	1.583.492.480	252.938.157
- <i>Actuarial Gains/(Losses) on Employee Benefits</i>	(8.791.736)	(1.238.083)
- <i>Shares of Other Comprehensive Income of Investments Valued by the Equity Method, Not to be Classified in Profit or Loss</i>	(143.831)	(38.934)
Other Accumulated Comprehensive Income (Expenses) to be Reclassified to Profit or Loss	144.881.024	55.993.439
- <i>Foreign Currency Conversion Differences</i>	144.881.024	55.993.439
Profit Reserved Restricted Reserves	78.622.024	36.867.423
Past Years Profits	162.445.260	64.604.605
Net Profit for the Period	712.885.211	139.595.256
	<b>2.815.061.698</b>	<b>728.195.506</b>

**Repurchased Shares**

Pursuant to the decision of the Board of Directors of the Company on February 1, 2022, the share buyback program was initiated. Within the scope of the current program, between February 2, 2022 and June 30, 2022, shares with a nominal value of TL 5,000,000, corresponding to 2.62% of the Company's capital, were bought back for TL 37,802,377. (December 31, 2021: The share repurchase program has been initiated based on the decision of the Board of Directors on June 30, 2021. Within the scope of the current program, between 1 July and 31 December 2021, a total nominal value of 5,000,000 TL, corresponding to 2.62% of the Company's capital, has been initiated. valuable share was bought back for TL 26,765,386.). Share repurchases are financed by the Company's cash and cash equivalents. As of 31 December 2022, no repurchased shares were sold.

In accordance with Article 520 of Law No. 6102, a reserve fund is set aside for the shares bought back in an amount that meets the acquisition value. As of 31 December 2022, the Group has set aside reserves for the repurchased shares amounting to TL 64.567.763 incurred during the purchase within the restricted reserves set aside from profit in its consolidated financial statements.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 23 – REVENUE AND COST OF SALES**

The revenue and cost of sales for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Revenue and Cost of Sales</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Domestic Sales Income	7.388.320.432	2.222.633.854
Overseas Sales Income	13.284.278.016	7.102.710.572
Other Income	79.051.611	7.998.295
<b>Gross Sales</b>	<b>20.751.650.059</b>	<b>9.333.342.721</b>
Sales Returns (-)	(153.715.714)	(19.579.410)
Sales Discounts (-)	(144.582.033)	(2.888.139)
Other Discounts	(18.926.066)	(2.129.617)
<b>Net Sales</b>	<b>20.434.426.246</b>	<b>9.308.745.555</b>
<b>Cost of Sales</b>	<b>(18.791.629.676)</b>	<b>(8.785.308.210)</b>
Cost of Merchandise Sold	(13.579.936.916)	(7.486.784.363)
Cost of Goods Sold	(5.179.486.576)	(1.287.150.541)
Cost of Services Sold	(32.206.184)	(11.373.306)
<b>Gross Profit/Loss</b>	<b>1.642.796.570</b>	<b>523.437.345</b>

The cost of sales for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Cost of Sales</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
<b>Cost of Goods Sold</b>	<b>(13.579.936.916)</b>	<b>(7.486.784.363)</b>
<b>Cost of Merchandise Sold</b>	<b>(5.179.486.576)</b>	<b>(1.287.150.541)</b>
<b>Cost of Services Sold</b>	<b>(32.206.184)</b>	<b>(11.373.306)</b>
Vehicle Expenses	(2.236.872)	(3.277.098)
Personnel Expenses	(3.316.282)	(3.988.591)
Amortization Expenses	(13.310.424)	(1.589.758)
Outsourced Benefits and Services	(2.761.503)	(1.580.896)
Insurance Expenses	(1.161.510)	(533.715)
Transport Expenses	(8.116.003)	(160.369)
Taxes, Duties and Charges	(176.913)	(134.468)
Other Expenses	(882.289)	(108.411)
Maintenance and Repair Expenses	(244.388)	-
	<b>(18.791.629.676)</b>	<b>(8.785.308.210)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 24 – GENERAL ADMINISTRATIVE EXPENSES AND MARKETING COSTS**

Total operating expenses for the periods ended December 31, 2022 and December 31, 2021 are as follows:

	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Marketing Expenses	(387.668.802)	(140.909.095)
General Administrative Expenses	(114.526.085)	(41.266.820)
Research and Development Expenses	(175.049)	(20.235)
	<b>(502.369.936)</b>	<b>(182.196.150)</b>

General administrative expenses for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>General Administrative Expenses</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Personnel expenses	(34.549.707)	(12.436.046)
Consulting Expenses	(11.370.057)	(6.486.748)
Late Fee and Penalties	(3.403)	(6.270.986)
Amortization Expenses	(14.054.742)	(2.772.443)
Outsourced Benefits and Services	(12.495.736)	(2.663.871)
Insurance Expenses	(2.210.747)	(1.685.751)
Other expenses	(8.854.124)	(1.630.095)
Taxes, Duties and Fees	(10.363.579)	(1.560.070)
Training and Publication Expenses	(4.179.676)	(964.689)
Rental Expenses	(2.803.109)	(807.787)
Donations and Grants	(1.710.722)	(674.539)
Vehicle Expenses	(1.735.329)	(478.783)
Transport Expenses	(1.620.935)	(467.068)
Representation and Hospitality Expenses	(1.395.199)	(464.073)
Food Expenses	(1.559.364)	(436.146)
Amortization Expenses of Leases	(257.780)	(338.778)
Electricity, Heating and Water Expenses	(1.186.331)	(238.117)
Accommodation Expenses	(60.919)	(234.967)
Advertising Expenses	(1.004.473)	(193.717)
Maintenance and Repair Expenses	(779.287)	(154.797)
Court Expenses	(212.217)	(117.078)
Registration and Announcement Expenses	(457.201)	(97.471)
Commission Expenses	-	(54.944)
Trademark, Patent Application and Renewal Expenses	(26.841)	(31.961)
Notary Expenses	(116.456)	(3.779)
Fair Expenses	(1.518.151)	(2.116)
	<b>(114.526.085)</b>	<b>(41.266.820)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 24 – GENERAL ADMINISTRATIVE EXPENSES AND MARKETING COSTS (Cont.)**

Marketing expenses for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Marketing Expenses</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Export Expenses	(186.239.565)	(87.154.840)
Shipping Costs	(122.894.675)	(35.941.880)
Personnel Expenses	(42.379.083)	(8.518.508)
Outsourced Benefits and Services	(3.859.032)	(1.646.830)
Commission Expenses	(1.554.554)	(1.499.429)
Vehicle Expenses	(4.740.994)	(1.300.893)
Amortization Expenses of Leases	(3.708.685)	(1.141.476)
Insurance Expenses	(191.117)	(930.236)
Taxes, Duties and Fees	(1.065.155)	(864.158)
Fair Expenses	(1.540.292)	(459.298)
Rental Expenses	(1.889.547)	(455.365)
Food Expenses	(1.655.124)	(362.349)
Other Expenses	(4.521.912)	(255.992)
Amortization Expenses	(4.248.491)	(117.119)
Transportation Expenses	(1.316.045)	(115.599)
Accommodation Expenses	(639.753)	(67.925)
Consulting Expenses	(57.308)	(42.797)
Late Fees and Penalties	(44.600)	(34.401)
Advertising and Promotion Expenses	(5.122.870)	-
	<b>(387.668.802)</b>	<b>(140.909.095)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 25 – OTHER INCOME AND EXPENSES FROM MAIN ACTIVITIES**

Other income from main activities for the periods ended December 31, 2022 and December 31, 2021 is as follows:

<b>Other Income from Main Activities</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Foreign Exchange Income on Trade Receivables and Payables	1.222.650.530	542.448.443
Maturity Income	165.549.471	54.818.067
Price Difference Revenues	31.490.193	23.629.520
Service Reflection Revenues	17.541.572	22.414.529
Off-topic Provisions	9.085.458	12.715.009
Rediscount Interest Income	26.931.541	11.994.495
Other Income	8.101.648	2.484.609
Licensed Warehouse Rental Support	-	1.821.801
Income Obtained from Law No. 5510 and 6661	2.879.335	1.400.561
Income from Incentives and Supports	1.719.215	820.824
Compensation Incomes	102.218	254.076
Income from Refunded Expenses	9.273.169	173.485
Balance Allocation Income	850.786	120.786
	<b>1.496.625.136</b>	<b>675.096.205</b>

Other expenses from main activities for the periods ended December 31, 2022 and December 31, 2021 is as follows:

<b>Other Expenses from Main Activities</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Exchange Difference Expenses Related to Trade Receivables and Payables	(737.805.097)	(178.553.750)
Maturity Interest Expense	(194.098.753)	(60.023.114)
Rediscount Interest Expenses	(43.662.797)	(11.340.331)
Refunded Expenses	(12.827.562)	(6.801.331)
Provision Expenses	(7.360.474)	(4.081.329)
Other Expenses	(8.138.700)	(2.666.380)
Price Difference Expenses	(2.646.679)	(2.099.328)
Balance Allocation Expenses	(91.387)	(492.391)
Tax Penalty Expenses	(39.718)	(170.862)
	<b>(1.006.671.167)</b>	<b>(266.228.816)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 26 – INCOME AND EXPENSES FROM INVESTING ACTIVITIES**

Income from investing activities for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Income from Investing Activities</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Investment Property Value Increase	692.000	3.428.315
Fixed Asset Sales Revenues	13.837.859	958.790
Investment Real Estate Sales Earnings	36.984.000	-
Currency Protected Deposit Fair Value Increase	30.031.125	-
	<b>81.544.984</b>	<b>4.387.105</b>

Expense from investing activities for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Expenses from Investing Activities</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Contingent Value Valuation Expense (Note 3)	(3.384.717)	-
Fixed Asset Sales Expenses	(65.271)	-
	<b>(3.449.988)</b>	<b>-</b>

Impairment Earnings/Losses and Cancelled Impairment Losses as per TFRS 9 are as follows:

	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Expected Credit Loss	(3.232.945)	(638.241)
	<b>(3.232.945)</b>	<b>(638.241)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 27 – FINANCE INCOME AND EXPENSES**

Finance income for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Finance Income</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Exchange Profits	464.257.275	333.203.357
Securities Valuation and Sales Profits	162.189.818	124.094.463
Derivative Financial Instrument Revenues and Fair Value Differences	140.958.725	107.845.226
Interest income	80.691.487	16.186.566
	<b>848.097.305</b>	<b>581.329.612</b>

Finance expense for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Finance Expenses</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Exchange Losses	(813.750.526)	(821.496.854)
Financing Expenses	(493.890.117)	(156.678.871)
Derivative Financial Instrument Expenses and Fair Value Differences	(153.797.452)	(115.553.047)
Losses on the Sale of Securities	(277.574.912)	(55.544.692)
Financing Expense Arising from Rental Obligation	(1.140.984)	(1.108.204)
	<b>(1.740.153.991)</b>	<b>(1.150.381.668)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

---

**FOOTNOTE 28 – INCOME TAXES****Corporate tax**

As of 31 December 2022, the corporate tax rate valid in Türkiye is 23%. With the amendment in the Corporate Tax Law published in the Official Gazette dated April 22, 2021 and numbered 31462, it will be applied at the rate of 25% for corporate earnings in 2021 and 23% for corporate earnings in 2022 in Türkiye. The said application will be effective starting from January 1, 2021.

In addition, as a result of the amendment made in the Corporate Tax Law No. 5520, the 75% exemption granted for the gains arising from the sale of the immovables that are in the assets of the institutions for at least two full years, effective as of January 1, 2018, will be applied as 50%.

According to Turkish tax legislation, financial losses can be carried forward for a maximum period of five years to be set off against the future income of the entity. Financial losses, however, cannot be set off from the previous years' profits.

The Company's subsidiary Rolweg is operating in Switzerland. Income tax in Switzerland is 12,5 percent

**Income tax withholding**

By the Presidential Decree dated 21.12.2021 and numbered 4936, by joint stock companies residing in Türkiye; The income tax withholding rate was reduced from 15% to 10% in dividend payments made to real persons residing in Türkiye, non-income and corporate taxpayers or exempted from these taxes, and real and legal persons who are not resident in Türkiye. Dividend payments made from joint stock companies residing in Türkiye to joint stock companies residing in Türkiye are not subject to tax withholding. In addition, if the profit is not distributed or added to the capital, no tax deduction is made.



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 28 – INCOME TAXES (Cont.)****Deferred tax assets and liabilities**

The Group calculates its taxable assets and liabilities taking into account the effect of temporary differences resulting from different assessment of balance sheet items in statutory financial statements and those prepared pursuant to the TFRS. Such temporary differences usually arise from recognition of income and expenses in different reporting periods pursuant to the TFRS and tax laws.

The Group's deferred tax assets and liabilities as of December 31, 2022 are as follows:

<b>31 December 2022- Deferred Tax Assets</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
Doubtful Receivables	12.945.694	3.158.520
Adjustment of Claims from Personnel	55.237	13.803
Adjustment of Advances Given	2.580.488	645.122
MDV and MODV Value Correction (*)	682.848.913	137.552.247
Inventory Impairment Expense and Other Inventory Adjustments	13.128.684	3.096.282
Amortized Cost Value Adjustment of Receivables	42.973.877	8.835.234
Amortized Cost Value Adjustment of Debts	3.790.421	923.751
Interest Accrual Adjustment	45.508.570	10.473.743
Derivative Instrument GUD Difference Adjustment	154.285.807	35.553.741
Exchange	79.365.337	18.225.739
Sell and Rent Fix	710.270	177.567
Credits Adjustment	51.104.874	12.407.012
Litigation Provisions	1.411.931	333.244
Rental Obligation	125.300	28.819
Investment Discount	18.324.661	3.968.206
Provisions for Unused Leave Days	2.090.136	480.731
Provisions for Severance Pay	19.633.983	4.515.816
Letter of Credit Rate Adjustment	11.904.878	2.738.122
Other Fixes	13.094.015	3.066.262
Severance Pay Actuarial Difference	5.526.658	1.271.131
	<b>1.161.409.734</b>	<b>247.465.092</b>

(\*) The Group has revalued its depreciable economic assets in its financial statements prepared in accordance with the Tax Procedure Law ("TPL"), and at the end of this transaction, a value increase fund amounting to TL 621.618.447 has been accounted for. Türkiye Financial This transaction has been canceled in the consolidated financial statements prepared in accordance with the Reporting Standards, and as a result, deferred tax assets amounting to TL 119.389.901 have been recorded.

In the scope of TAS 12 Income Tax Standard, based on the reduction of temporary differences calculated by the Group, which has already adopted the revaluation model for land and land, underground and surface improvements, facilities, machinery and equipment and vehicles, the value increase of the said economic assets in TFRS. The part of the calculated deferred tax liability corresponding to the difference is canceled. The deferred tax amount of TL 103,354,989 calculated for this cancellation is directly reflected in the consolidated other comprehensive income statement. The portion of 16,034,912 TL, which is related to the fixed assets that are not followed up with the revaluation model in TFRS, is reflected in the consolidated profit or loss statement.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 28 – INCOME TAXES (Cont.)**

<b>31 December 2022- Deferred Tax Liabilities</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
MDV and MODV Value Correction	1.766.247.883	343.324.528
Investment Property Valuation	692.000	79.580
Derivative Instrument GUD Difference Adjustment	87.962.074	21.990.519
Inventory Impairment Expense and Other Inventory Adjustments	26.569.146	6.341.168
Letter of Credit Rate Adjustment	11.330.639	2.613.610
Amortized Cost Value Adjustment of Receivables	11.211.180	2.597.312
Doubtful Receivables	13.246.083	3.236.558
Interest Accrual Adjustment	29.577.862	6.810.917
Credits Adjustment	49.452.388	12.024.874
Rental Obligation	1.481.463	341.219
Provisions for Unused Leave Days	2.000.685	460.158
Exchange	101.119.334	23.089.115
Other Fixes	20.489.165	4.712.701
Competition Authority Cancellation of Penalty	5.519.158	1.309.102
Income Accruals (*)	127.569.070	29.340.886
Amortized Cost Value Adjustment of Debts	3.378.547	745.038
Provisions for Severance Pay	20.211.834	4.649.052
Severance Pay Actuarial Difference	4.588	1.055
	<b>2.278.063.099</b>	<b>463.667.392</b>

(\*) See Footnote 8.

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 28 – INCOME TAXES (Cont.)**

As of 31 December 2021, the items that make up the Group's deferred tax assets and liabilities are as follows:

<b>31 December 2021- Deferred Tax Assets</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
Doubtful Receivables	10.608.296	2.309.065
Adjustment of Claims from Personnel	69.016	13.803
Adjustment of Advances Given	3.225.609	645.122
Value Adjustment for Tangible Assets and Intangible Assets	81.321.826	16.693.332
Inventory Impairment Expense and Other Inventory Adjustments	4.816.498	969.119
Amortized Cost Value Adjustment of Receivables	11.198.905	2.657.989
Amortized Cost Value Adjustment of Debts	2.823.778	701.479
Interest Accrual Adjustment	354.934	84.641
Derivative Instrument GUD Difference Adjustment	3.400.255	850.064
exchange rate	36.681.740	9.153.492
Sell and Rent Fix	710.270	177.567
Credits Adjustment	16.911.136	8.161.141
Litigation Provisions	425.000	106.250
Accounting Policy Change	541.307	75.315
Provisions for Severance Pay	1.628.498	402.509
Letter of Credit Rate Adjustment	10.952.486	2.738.122
Severance Pay Actuarial Difference	1.483.650	316.987
Other Fixes	6.287.774	1.446.188
Investment Discount	18.324.661	3.968.206
	<b>211.765.639</b>	<b>51.470.391</b>
<b>31 December 2021- Deferred Tax Liabilities</b>	<b>Temporary Differences</b>	<b>Deferred Tax Effect</b>
Value Adjustment for Tangible Assets and Intangible Assets	351.649.759	65.621.035
Inventory Impairment Expense and Other Inventory Adjustments	11.513.230	2.878.307
Amortized Cost Value Adjustment of Receivables	2.682.352	642.082
Derivative Instrument GUD Difference Adjustment	88.610.579	21.990.519
Letter of Credit Rate Adjustment	378.153	94.538
Doubtful Receivables	9.497.954	2.374.488
Credits Adjustment	32.541.252	8.135.313
Rental Obligation	24.107	6.027
Interest Accrual Adjustment	400.441	100.110
Amortized Cost Value Adjustment of Debts	2.885.036	580.004
exchange rate	36.639.037	8.272.879
Provisions for Unused Leave Days	685	158
Severance Pay Actuarial Difference	4.588	1.055
Provisions for Severance Pay	10.381.879	2.222.205
Adjustment of Claims from Personnel	120	24
Competition Authority Cancellation of Penalty	6.192.069	1.238.414
Other Fixes	3.221.246	805.311
	<b>556.622.487</b>	<b>114.962.469</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 28 – INCOME TAXES (Cont.)**

	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Tax Income/Expense for the Period	(108.883.709)	(17.614.285)
Deferred Tax Income/Expense	5.051.464	(28.796.770)
	<b>(103.832.245)</b>	<b>(46.411.055)</b>
<b>Tax Liability for the Current Period Profit</b>		
	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Provisions for Tax on Current Period Profit and Other Legal Liabilities	108.883.709	17.614.284
Prepaid Tax and Other Liabilities Related to the Current Period Profit	(108.883.709)	(17.614.284)
	-	-

**FOOTNOTE 29 – EARNINGS PER SHARE**

Earnings per share for the periods ended December 31, 2022 and December 31, 2021 are as follows:

	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Net Profit/Loss for the Period	712.885.211	139.595.256
Weighted Average Number of Ordinary Shares in Circulation	181.979.925	189.256.175
<b>Earnings Per Share</b>	<b>3,9174</b>	<b>0,7376</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 30 – RELATED PARTY DISCLOSURES**

Related party disclosures for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Receivables from Related Parties</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	101.569.916	375.857
	<b>101.569.916</b>	<b>375.857</b>
<b>Notes Receivable from Related Parties</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	-	5.478.936
	<b>-</b>	<b>5.478.936</b>
<b>Other Receivable from Related Parties</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	-	600
	<b>-</b>	<b>600</b>
<b>Trade Payables to Related Parties</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	3.695.900	5.485.122
Ulusoy Petrol Ürünleri Tic. A.Ş.	266.419	87.440
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	15.903	223.142
Ulusoy Çay Gıda San. ve Tic. A.Ş.	125.587	23.920
GFC Denizcilik ve Ticaret A.Ş.	13.405	2.760
	<b>4.117.214</b>	<b>5.822.384</b>
<b>Other Payables to Related Parties</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	205.312.078	8.707.586
	<b>205.312.078</b>	<b>8.707.586</b>
<b>Advances Given for Purchases to Related Parties</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	9.469.792	6.898.543
	<b>9.469.792</b>	<b>6.898.543</b>
<b>Order Advances Received From Related Parties</b>	<b>December 31, 2022</b>	<b>December 31, 2021</b>
GFC Denizcilik ve Ticaret A.Ş.	-	428.212
	<b>-</b>	<b>428.212</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 30 – RELATED PARTY DISCLOSURES (Cont.)**

Related party disclosures for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>Sales Revenues from Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	154.381.687	135.783.887
Eren Gülhan Ulusoy	2.100	4.067
	<b>154.383.787</b>	<b>135.787.954</b>
<b>Purchases from Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Ulusoy Çay Gıda San. ve Tic. A.Ş.	34.061	47.230
Unay Un San. ve Tic. A.Ş.	520.024.619	198.448.077
Ulusoy Petrol Ürünleri Tic. A.Ş.	1.972.506	2.099.234
GFC Denizcilik ve Ticaret A.Ş.	19.103	26.428
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	5.356.468	4.757.922
	<b>527.406.757</b>	<b>205.378.891</b>
<b>Other Income from Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	80.956	788.687
GFC Denizcilik ve Ticaret A.Ş.	2.009.119	18.000
	<b>2.090.075</b>	<b>806.687</b>
<b>General Production and Service Expenses to Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	(6.000)	(39.394)
Ulusoy Petrol Ürünleri Tic. A.Ş.	(122.275)	(75.970)
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	(119.977)	-
	<b>(248.252)</b>	<b>(115.364)</b>
<b>Marketing Expenses to Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	(2.850.751)	(243.804)
Ulusoy Petrol Ürünleri Tic. A.Ş.	(2.935.159)	(531.968)
GFC Denizcilik ve Ticaret A.Ş.	(9.123)	-
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	(63.343)	(992)
	<b>(5.858.376)</b>	<b>(776.764)</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 30 – RELATED PARTY DISCLOSURES (Cont.)**

Related party disclosures for the periods ended December 31, 2022 and December 31, 2021 are as follows:

<b>General Administrative Expenses to Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Ulusoy Petrol Ürünleri Tic. A.Ş.	(742.735)	(68.348)
Unay Un San. ve Tic. A.Ş.	(30.394)	(13.446)
GFC Denizcilik ve Ticaret A.Ş.	(13.016)	(2.076)
Ulusoy Çay Gıda San. Ve Tic. A.Ş.	(58.190)	
Fahrettin Ulusoy	-	(10.500)
Sasbaş Samsun Serbest Bölgesi Kurucu ve İşletmecisi A.Ş.	(69.294)	(257.645)
	<b>(913.629)</b>	<b>(352.015)</b>
<b>Other Expenses to Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	(69.666)	(75.385)
Ulusoy Petrol Ürünleri Tic. A.Ş.	-	(39.172)
	<b>(69.666)</b>	<b>(114.557)</b>
<b>Finance Expenses to Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	(29.017.927)	(10.806.993)
	<b>(29.017.927)</b>	<b>(10.806.993)</b>
<b>Financial Revenues from Related Parties</b>	<b>January 1- December 31, 2022</b>	<b>January 1- December 31, 2021</b>
Unay Un San. ve Tic. A.Ş.	7.691.916	4.233.103
	<b>7.691.916</b>	<b>4.233.103</b>

The Group's senior management consists of board members, general manager and department managers. The benefits and fees provided by the Group to its senior management as of December 31, 2022 are 16.943.872 TRY (December 31, 2021: 3.323.500 TRY).

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 31 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS****Credit Risk**

December 31, 2022	Receivables				Bank Deposits	Derivative instruments	Others
	Trade receivables		Other receivables				
	Related party	Related party	Related party	Related party			
Maximum credit risk as of the date of the report (A+B+C+D+E+F)	101.569.916	2.855.465.691	-	58.519.973	1.506.164.864	144.075.641	13.539.912
- The portion of the maximum risk hedged by collateral, etc.							
A. Net book value of the financial assets that are not overdue or impaired	101.569.916	2.858.698.636	-	58.519.973	1.506.164.864	144.075.641	13.539.912
B. Net book value of the financial assets the conditions of which were renegotiated, or otherwise deemed to be overdue or impaired	-	-	-	-	-	-	-
C. Net book value of the financial assets that are overdue, but not impaired	-	-	-	-	-	-	-
- The portion hedged by collaterals, etc.	-	-	-	-	-	-	-
D. Net book value of the assets that are impaired	-	-	-	-	-	-	-
- Past due (gross book value)	-	-	-	-	-	-	-
- Impairment (-)	-	-	-	-	-	-	-
- Undue (gross book value)	-	8.197.828	-	-	-	-	-
- Impairment (-)	-	(8.197.828)	-	-	-	-	-
E. Components involving off-balance sheet credits	-		-	-	-	-	-
F. Expected Credit Loss	-	(3.232.945)	-	-	-	-	-



**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 31 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Cont.)****Credit Risk (Cont.)**

December 31, 2021	Receivables				Bank Deposits	Derivative instruments	Others
	Trade receivables		Other receivables				
	Related party	Related party	Related party	Related party			
Maximum credit risk as of the date of the report (A+B+C+D+E+F)	5.854.793	1.157.404.123	600	5.405.231	498.783.391	225.374.770	117.579
- The portion of the maximum risk hedged by collateral, etc.							
A. Net book value of the financial assets that are not overdue or impaired	5.854.793	1.158.042.364	600	5.405.231	498.783.391	225.374.770	117.579
B. Net book value of the financial assets the conditions of which were renegotiated, or otherwise deemed to be overdue or impaired	-		-	-	-	-	-
C. Net book value of the financial assets that are overdue, but not impaired	-		-	-	-	-	-
- The portion hedged by collaterals, etc.	-		-	-	-	-	-
D. Net book value of the assets that are impaired	-		-	-	-	-	-
- Past due (gross book value)	-		-	-	-	-	-
- Impairment (-)	-		-	-	-	-	-
- Undue (gross book value)	-	6.815.828	-	-	-	-	-
- Impairment (-)	-	(6.815.828)	-	-	-	-	-
E. Components involving off-balance sheet credits	-		-	-	-	-	-
F. Expected Credit Loss	-	(638.241)	-	-	-	-	-

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 31 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Cont.)****Liquidity risk**

<b>December 31, 2022</b>						
<b>Non-derivative Financial Liabilities</b>	<b>Book Value</b>	<b>Total cash outflow under the Contract (I+II+III+IV)</b>	<b>Less than 3 months (I)</b>	<b>3–12 months (II)</b>	<b>1–5 years (III)</b>	<b>More than 5 years (IV)</b>
Bank Loans	3.233.199.333	3.233.199.333	711.118.923	1.682.086.194	835.526.785	4.467.431
Trade Payables	3.083.354.814	3.083.354.814	1.590.177.450	1.493.177.364	-	-
Other Payables	205.591.252	205.591.252	-	205.591.252	-	-
<b>Total Liabilities</b>	<b>6.522.145.399</b>	<b>6.522.145.399</b>	<b>2.301.296.373</b>	<b>3.380.854.810</b>	<b>835.526.785</b>	<b>4.467.431</b>

<b>December 31, 2021</b>						
<b>Non-derivative Financial Liabilities</b>	<b>Book Value</b>	<b>Total cash outflow under the Contract (I+II+III+IV)</b>	<b>Less than 3 months (I)</b>	<b>3–12 months (II)</b>	<b>1–5 years (III)</b>	<b>More than 5 years (IV)</b>
Bank Loans	1.600.110.505	1.600.110.505	221.493.871	1.096.365.508	273.837.815	8.413.311
Trade Payables	1.139.289.953	1.139.289.953	494.768.637	644.521.316	-	-
Other Payables	8.835.403	8.835.403	-	8.835.403	-	-
<b>Total Liabilities</b>	<b>2.748.235.861</b>	<b>2.748.235.861</b>	<b>716.262.508</b>	<b>1.749.722.227</b>	<b>273.837.815</b>	<b>8.413.311</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 31 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Cont.)****Foreign Currency Risk**

	December 31, 2022			
	TRY equivalent	USD	EUR	Other
1. Trade receivables	1.028.917.322	54.349.482	28.014	46.632.515
2a. Monetary financial assets (including cash bank accounts)	789.864.296	41.954.657	195.409	4.487.957
2b. Non-monetary financial assets	-	-	-	-
3. Other	28.696.675	1.534.721	-	-
<b>4. Current assets (1+2+3)</b>	<b>1.847.478.293</b>	<b>97.838.860</b>	<b>223.423</b>	<b>51.120.472</b>
5. Trade receivables	-	-	-	-
6a. Monetary financial assets	-	-	-	-
6b. Non-monetary financial assets	-	-	-	-
7. Other	-	-	-	-
<b>8. Non-current assets (5+6+7)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9. Total assets (4+8)</b>	<b>1.847.478.293</b>	<b>97.838.860</b>	<b>223.423</b>	<b>51.120.472</b>
10. Trade payables	2.554.342.331	135.902.048	431.889	-
11. Financial liabilities	537.178.231	28.677.036	-	-
12a. Other monetary liabilities	-	-	-	-
12b. Other non-monetary liabilities	-	-	-	-
<b>13. Short-term liabilities (10+11+12)</b>	<b>3.091.520.562</b>	<b>164.579.084</b>	<b>431.889</b>	<b>-</b>
14. Trade payables	-	-	-	-
15. Financial liabilities	435.331.056	23.239.967	-	-
16 a. Other monetary liabilities	-	-	-	-
16 b. Other non-monetary liabilities	-	-	-	-
<b>17. Long-term liabilities (14+15+16)</b>	<b>435.331.056</b>	<b>23.239.967</b>	<b>-</b>	<b>-</b>
<b>18. Total liabilities (13+17)</b>	<b>3.526.851.618</b>	<b>187.819.050</b>	<b>431.889</b>	<b>-</b>
19. Net asset/liability position of off-balance sheet derivative financial instruments (19a-19b)	130.032.885	6.954.262	-	-
19a. Total amount of hedged assets	130.032.885	6.954.262	-	-
19b. Total amount of hedged liabilities	-	-	-	-
<b>20. Net foreign currency asset/liability position (9-18+19)</b>	<b>(1.549.340.440)</b>	<b>(83.025.929)</b>	<b>(208.466)</b>	<b>51.120.472</b>
<b>21. Total fair value of financial instruments used for foreign currency hedging (1+2a+3+5+6a-10-11-12a-14-15-16a)</b>	<b>(1.679.373.325)</b>	<b>(89.980.191)</b>	<b>(208.466)</b>	<b>51.120.472</b>
21. Export (Average Exchange Rate)	1.882.609.539	96.661.453	16.185.369	7.466
21. Import (Average Exchange Rate)	3.703.433.627	196.791.958	14.765.013	269.870.187

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 31 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Cont.)****Foreign Currency Risk**

	December 31, 2021			
	TRY equivalent	USD	EUR	Other
1. Trade receivables	1.046.286.205	77.423.047	785.284	12.275.193
2a. Monetary financial assets (including cash bank accounts)	447.534.816	33.153.827	346.722	26.665
2b. Non-monetary financial assets	-	-	-	-
3. Other	67.508	5.065	-	-
<b>4. Current assets (1+2+3)</b>	<b>1.493.888.530</b>	<b>110.581.939</b>	<b>1.132.006</b>	<b>12.301.858</b>
5. Trade receivables	-	-	-	-
6a. Monetary financial assets	86.404.603	6.482.452	-	-
6b. Non-monetary financial assets	-	-	-	-
7. Other	-	-	-	-
<b>8. Non-current assets (5+6+7)</b>	<b>86.404.603</b>	<b>6.482.452</b>	-	-
<b>9. Total assets (4+8)</b>	<b>1.580.293.133</b>	<b>117.064.391</b>	<b>1.132.006</b>	<b>12.301.858</b>
10. Trade payables	1.165.053.132	87.024.400	198.796	650
11. Financial liabilities	558.424.544	41.820.156	-	-
12a. Other monetary liabilities	-	-	-	-
12b. Other non-monetary liabilities	-	-	-	-
<b>13. Short-term liabilities (10+11+12)</b>	<b>1.723.477.676</b>	<b>128.844.556</b>	<b>198.796</b>	-
14. Trade payables	-	-	-	-
15. Financial liabilities	134.112.074	10.043.592	-	-
16 a. Other monetary liabilities	-	-	-	-
16 b. Other non-monetary liabilities	-	-	-	-
<b>17. Long-term liabilities (14+15+16)</b>	<b>134.112.074</b>	<b>10.043.592</b>	-	-
<b>18. Total liabilities (13+17)</b>	<b>1.857.589.750</b>	<b>138.888.148</b>	<b>198.796</b>	-
19. Net asset/liability position of off-balance sheet derivative financial instruments (19a-19b)	161.002.874	12.079.141	-	-
19a. Total amount of hedged assets	161.002.874	12.079.141	-	-
19b. Total amount of hedged liabilities	-	-	-	-
<b>20. Net foreign currency asset/liability position (9-18+19)</b>	<b>(116.293.743)</b>	<b>(9.744.615)</b>	<b>933.210</b>	<b>12.301.858</b>
<b>Total fair value of financial instruments used for foreign currency hedging (1+2a+3+5+6a-10-11-12a-14-15-16a)</b>	<b>(277.296.617)</b>	<b>(21.823.757)</b>	<b>933.210</b>	<b>12.301.208</b>
21. Export (Average Exchange Rate)	724.088.688	74.362.044	6.279.283	-
21. Import (Average Exchange Rate)	533.538.629	57.129.291	2.645.273	-

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 30 – NATURE AND LEVEL OF RISKS ASSOCIATED WITH FINANCIAL INSTRUMENTS (Cont.)****Foreign Currency Risk (Cont.)**

The following table shows the Group's sensitivity to a 10 percent increase and decrease in the exchange rates. This sensitivity analysis covers only the open foreign currency monetary items at the end of the period, and shows the effects of a 10 percent change in foreign currency rates on the items. Positive values refer to increases in profit/loss and other equity items.

Statement of exchange rate sensitivity analysis				
December 31, 2022				
	Profit/loss		Equities	
	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION
In the event of USD increasing/decreasing 10% in value against TRY				
1- Net assets/liabilities in USD	(168.880.610)	168.880.610	(168.880.610)	168.880.610
2- The portion hedged against the USD risk (-)				-
<b>3- USD net effect (1+2)</b>	<b>(168.880.610)</b>	<b>168.880.610</b>	<b>(168.880.610)</b>	<b>168.880.610</b>
In the event of EUR increasing/decreasing 10% in value against TRY				
4- Net assets/liabilities in EUR	(417.126)	417.126	(417.126)	417.126
5- The portion hedged against the EUR risk (-)				-
<b>6- EUR net effect (4+5)</b>	<b>(417.126)</b>	<b>417.126</b>	<b>(417.126)</b>	<b>417.126</b>
In the event of GBP increasing/decreasing 10% in value against TRY				
7- Other net assets/liabilities	1.360.403	(1.360.403)	1.360.403	(1.360.403)
8- The portion hedged against other risks (-)				-
<b>9- Other net effect (7+8)</b>	<b>1.360.403</b>	<b>(1.360.403)</b>	<b>1.360.403</b>	<b>(1.360.403)</b>
<b>Total (3+6+9)</b>	<b>(167.937.333)</b>	<b>167.937.333</b>	<b>(167.937.333)</b>	<b>167.937.333</b>

Statement of exchange rate sensitivity analysis				
December 31, 2021				
	Profit/loss		Equities	
	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION	FOREIGN CURRENCY APPRECIATION	FOREIGN CURRENCY DEPRECIATION
In the event of USD increasing/decreasing 10% in value against TRY				
1- Net assets/liabilities in USD	(29.422.217)	29.422.217	(29.422.217)	29.422.217
2- The portion hedged against the USD risk (-)				-
<b>3- USD net effect (1+2)</b>	<b>(29.422.217)</b>	<b>29.422.217</b>	<b>(29.422.217)</b>	<b>29.422.217</b>
In the event of EUR increasing/decreasing 10% in value against TRY				
4- Net assets/liabilities in EUR	1.407.365	(1.407.365)	1.407.365	(1.407.365)
5- The portion hedged against the EUR risk (-)				-
<b>6- EUR net effect (4+5)</b>	<b>1.407.365</b>	<b>(1.407.365)</b>	<b>1.407.365</b>	<b>(1.407.365)</b>
In the event of GBP increasing/decreasing 10% in value against TRY				
7- Other net assets/liabilities	285.190	(285.190)	285.190	(285.190)
8- The portion hedged against other risks (-)				-
<b>9- Other net effect (7+8)</b>	<b>285.190</b>	<b>(285.190)</b>	<b>285.190</b>	<b>(285.190)</b>
<b>Total (3+6+9)</b>	<b>(27.729.662)</b>	<b>27.729.662</b>	<b>(27.729.662)</b>	<b>27.729.662</b>

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 32 – FINANCIAL INSTRUMENTS (FAIR VALUE DISCLOSURES AND OTHER DISCLOSURES CONCERNING HEDGE ACCOUNTING)****Fair Value of Financial Instruments**

Based on the source of valuation inputs of each financial instrument class, the Group categorizes the financial instruments recognized at fair value according to the three-level hierarchy.

Level 1: Valuation techniques using quoted prices in active markets for identical assets or liabilities that the Group has the ability to access at the measurement date;

Level 2: Other valuation techniques involving inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly;

Level 3: Valuation techniques using unobservable inputs for the assets or liability.

<b>Financial Assets (December 31, 2022)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative assets	-	144.075.641	-
Short-term Financial Investments	1.047.908.349	-	-
<b>Financial liabilities (December 31, 2022)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative liabilities	-	65.554.675	-
Short-term Financial Investments	-	-	-
<b>Financial Assets (December 31, 2021)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative assets	-	225.374.770	-
Short-term Financial Investments	36.038.234	-	-
<b>Financial liabilities (December 31, 2021)</b>	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>
Derivative liabilities	-	55.543	-
Short-term Financial Investments	-	-	-

**ULUSOY UN SANAYİ VE TİCARET A.Ş.**

Notes to the Consolidated Financial Statements as of December 31, 2022

(Unless otherwise stated, amounts are expressed in Turkish Lira ("TRY").)

**FOOTNOTE 33 – FEES FOR SERVICES RECEIVED FROM INDEPENDENT AUDITOR'S**

Which was prepared by the POA pursuant to the Board Decision published in the Official Gazette on 30 March 2021, and the preparation principles of which were based on the POA letter dated 19 August 2021, the explanation of the Group regarding the fees for the services rendered by the independent audit firms are as follows:

	January 1- December 31, 2022	January 1- December 31, 2021
Independent Audit Fee for the Reporting Period	1.113.000	509.700
	<b>1.113.000</b>	<b>509.700</b>

(\*) The fees above have been determined by including the legal audit fees of all subsidiaries, and the foreign currency fees of foreign subsidiaries have been converted into TRY using the annual average rates of the relevant years.

**FOOTNOTE 34 – EVENTS AFTER BALANCE SHEET DATE**

- The shares of Söke Değirmencilik Sanayi ve Ticaret A.Ş., a 100% subsidiary of the Company, which were offered to the public by collecting demand with a unit price of 7.50 TL between 4-5-6 January 2023, are on Yıldız Market as of 12 January 2023. also started trading. The issued capital of Söke Değirmencilik was increased from 309.000.000 TL to 386.500.000 TL with the decision of the Board of Directors registered at the Söke Trade Registry on February 8, 2023, and the increased amount of 77.500.000 B units with a nominal value of 77.500.000 TL was increased. group registered shares were offered to the public.

- In order to meet the electrical energy needs of Söke Değirmencilik's factories in Aydın-Söke and Ankara-Sincan from renewable energy sources, an agreement was reached with the solution partner company for the construction of an 8000 kWe solar power plant in Konya as of January 16, 2023, and necessary legal permits were obtained. Applications were made to official institutions and organizations for

- In order to increase the product variety, the company started the project studies for the pasta production line with a capacity of 37.200 tons/year in Samsun Food Organized Industrial Zone and issued the incentive certificate on January 30, 2023.

- As of January 31, 2023, applications were made to official institutions and organizations for the necessary legal permissions in order to establish a wind power plant with a total power of 22,360 kWe in the provinces of Manisa and İzmir in order to meet the electricity consumption of the Company, Samsun 50th Anniversary, and the production facilities in Merkez and Çorlu from renewable energy sources.

- Within the framework of the decision of the Board of Directors of the Company dated February 20, 2023, it has been decided to carry out share buyback programs and transactions with a maximum of 2,500,000 shares and to submit them to the information of the first General Assembly to be held. Within the framework of this Decision, between 24 February 2023 and 9 March 2023, shares with a nominal value of 188,000 TL were bought back against 5,289,823 TL.